```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 08:18:16 ON 17 JUL 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 17 Jul 2003  VOL 139 ISS 3
FILE LAST UPDATED: 16 Jul 2003  (20030716/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=> d his

     (FILE 'HOME' ENTERED AT 07:49:57 ON 17 JUL 2003)
               DEL HIS

     FILE 'HCAPLUS' ENTERED AT 07:52:43 ON 17 JUL 2003
               E WO2000-EP6139/AP,PRN
L1           1 S E3,E4
               SEL RN

     FILE 'REGISTRY' ENTERED AT 07:53:38 ON 17 JUL 2003
L2          67 S E1-E67

     FILE 'HCAPLUS' ENTERED AT 07:57:03 ON 17 JUL 2003
               E BOVIN N/AU
L3         225 S E3,E5-E15
               E TUSIKOV A/AU
L4           1 S E4
               E CHINAREV A/AU
L5           7 S E4-E8
               E DICUSAR M/AU
L6           1 S E4
               E GAMBARIAN A/AU
               E GAMBARIYAN A/AU
L7           1 S E4
               E MARININA V/AU
L8          11 S E4,E6
L9         230 S L3-L8 NOT L1

     FILE 'REGISTRY' ENTERED AT 07:59:12 ON 17 JUL 2003

     FILE 'HCAPLUS' ENTERED AT 07:59:12 ON 17 JUL 2003
               SET SMARTSELECT ON
L10         SEL L9 1- RN :    1116 TERMS
               SET SMARTSELECT OFF

     FILE 'REGISTRY' ENTERED AT 07:59:20 ON 17 JUL 2003
L11        1116 S L10
L12          11 S 3392-07-2 OR 29248-48-4 OR 51513-80-5 OR 53546-95-5 OR 137125
```

```
L13          56 S L2 NOT L12
L14        1108 S L11 NOT L2

     FILE 'HCAPLUS' ENTERED AT 08:01:23 ON 17 JUL 2003
L15          47 S L13
L16           2 S L9 AND L15
                E TUZIKOV A/AU
L17          53 S E3-E10
                E GAMBARYAN A/AU
L18          47 S E3-E9
L19          44 S L17,L18 NOT L9
L20          44 S L19 NOT L1

     FILE 'REGISTRY' ENTERED AT 08:03:02 ON 17 JUL 2003

     FILE 'HCAPLUS' ENTERED AT 08:03:02 ON 17 JUL 2003
                SET SMARTSELECT ON
L21          SEL L20 1- RN :     109 TERMS
                SET SMARTSELECT OFF

     FILE 'REGISTRY' ENTERED AT 08:03:04 ON 17 JUL 2003
L22         109 S L21
L23         109 S L22 NOT L2
L24         107 S L23 NOT 11

     FILE 'HCAPLUS' ENTERED AT 08:03:22 ON 17 JUL 2003
L25           2 S L17-L20 AND L15
L26           2 S L16,L25
L27          45 S L15 NOT L26
L28          42 S L27 AND (PD<=20000630 OR PRD<=20000630 OR AD<=20000630)
L29          11 S L28 AND P/DT
L30          10 S L29 NOT L1
L31          31 S L28 NOT L29
L32           3 S L27 NOT L28
L33     1090772 S L24

     FILE 'REGISTRY' ENTERED AT 08:12:09 ON 17 JUL 2003
                SEL RN L22 100-109
L34          99 S L22 NOT E1-E10
L35          98 S L34 NOT 99-35-4
L36           3 S L35 AND OC5/ES

     FILE 'HCAPLUS' ENTERED AT 08:13:51 ON 17 JUL 2003
                E US6310043/PN
L37           3 S E3
                SEL RN

     FILE 'REGISTRY' ENTERED AT 08:15:09 ON 17 JUL 2003
L38          46 S E1-E46

     FILE 'HCAPLUS' ENTERED AT 08:16:24 ON 17 JUL 2003
L39           6 S L1,L16,L37
L40           6 S L39 AND L1,L3-L9,L15-L20,L25-L33,L37,L39
L41           6 S L40 AND L2,L11,L22,L38

     FILE 'HCAPLUS' ENTERED AT 08:18:16 ON 17 JUL 2003

=> d all hitstr tot l41

L41  ANSWER 1 OF 6  HCAPLUS  COPYRIGHT 2003 ACS
AN   2001:792325  HCAPLUS
DN   135:313605
TI   Compounds, including saccharide compounds, for treatment of bacterial
```

infections, and preparation thereof
IN Bundle, David R.; Kitov, Pavel; Read, Randy J.; Ling, Hong; Armstrong, Glen
PA Governors of the University of Alberta, Can.
SO U.S., 47 pp., Cont.-in-part of U.S. 5,962,423.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K031-70
ICS C12Q001-04
NCL 514025000
CC 1-5 (Pharmacology)
Section cross-reference(s): 33, 63
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI US 6310043	B1	20011030	US 1999-317290	19990524	<--
US 5962423	A	19991005	US 1998-130495	19980807	
CA 2339198	AA	20000217	CA 1999-2339198	19990806	
WO 2000008467	A2	20000217	WO 1999-CA725	19990806	
WO 2000008467	A3	20000706			
W: AU, CA, JP					
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
AU 9951450	A1	20000228	AU 1999-51450	19990806	
AU 754331	B2	20021114			
EP 1102779	A2	20010530	EP 1999-936219	19990806	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
PRAI US 1998-130495	A2	19980807			
US 1999-317290	A	19990524			
WO 1999-CA725	W	19990806			

AB Compds. which bind to toxins assocd. with enteric bacterial infection, compns. including the compds., methods for the neutralization of toxins in a patient, and methods for the diagnosis of bacterial and viral infections are disclosed. Toxins which can be bound by the compds. include pentameric toxins, for example SLTs (shiga-like toxins), such as those from Salmonella, Campylobacter and other bacteria, verotoxins from E. coli, cholera toxin, Clostridium difficile toxins A and B, bacterial pili from enteropathogenic E. coli and enterotoxigenic E. coli and viral lectins, such as viral hemagglutinins. The compds. include a core mol. bound to a plurality of linker arms, which in turn are bound to a plurality of bridging moieties, which in turn are bound to at least one, and preferably, two or more ligands which bind to the toxin. Examples of suitable ligands include di- and for trisaccharide moieties. The di- or tri-saccharide moieties themselves are active in binding to the SLTs. The presence of a plurality of bridged dimers of the ligands is responsible for the increased binding affinity of the compds. relative to the ligands themselves. In one embodiment, the compds., when administered in a timely fashion to a patient suffering from enteric E. coli infection, inhibit progression of this infection into hemolytic uremic syndrome (HUS).

ST dendrimer oligosaccharide Prepn antibacterial; antibacterial bacterial toxin saccharide deriv prepn; bacteria virus infection diagnosis; Escherichia hemolytic uremic syndrome saccharide deriv
IT Toxins
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(B, Clostridium difficile; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)
IT Toxins
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL

(Biological study)
(Shiga-like toxin I; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Toxins
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(Shiga-like toxin II; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Toxins
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(Shiga-like toxin; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Carbohydrates, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(aldaric acids; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Peptides, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(amino acids; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Infection
(bacterial, diagnosis; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Toxins
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(cholera; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Antibacterial agents
Campylobacter
Drug delivery systems
Salmonella
(compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Toxins
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Dendritic polymers
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Agglutinins and Lectins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Amino acids, biological studies
Disaccharides
Monosaccharides
Oligosaccharides, biological studies
Trisaccharides
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Escherichia coli
(enterotoxigenic; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)
IT Pilus
(from enteropathogenic E. coli; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)
IT Drug delivery systems
(injections; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)
IT Fluorescent substances
(label; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)
IT Enzymes, biological studies
Radionuclides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(label; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)
IT Drug delivery systems
(oral; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)
IT Intestinal bacteria
(pathogenic, pili from enteropathogenic E. coli; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)
IT Escherichia coli
(pili from enteropathogenic E. coli; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)
IT Alcohols, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(polyhydric; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)
IT Albumins, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(saccharide derivs.; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)
IT Toxins
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(toxin A, Clostridium difficile; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)
IT Clostridium difficile
(toxins A and B; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)
IT Virus
(viral lectin; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)
IT **258873-66-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)
IT **79-06-1D**, Acrylamide, derivs. **574-93-6D**, Phthalocyanine, derivs. **12619-70-4D**, Cyclodextrin, derivs. **13117-26-5D**, derivs. **54832-51-8D**, derivs. **66580-68-5D**, derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)
IT **58-85-5 9013-20-1**, Streptavidin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(label; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT **244076-91-3P 244076-92-4P 244076-93-5P**
244076-96-8P 244076-97-9P 244076-98-0P
244076-99-1P 244077-00-7P 244077-01-8P
244077-02-9P 244077-03-0P 244077-04-1P
244077-05-2P 244077-06-3P 244077-07-4P
244077-08-5P 244077-09-6P 258857-10-2P
258857-11-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT **98-88-4**, Benzoyl chloride **100-39-0 106-95-6**,
Allyl bromide, reactions **107-15-3**, 1,2-Ethanediamine, reactions
373-44-4, 1,8-Octanediamine **616-29-5**,
1,3-Diamino-2-hydroxypropane **1125-88-8 2365-48-2**,
Methyl thioglycolate **5231-87-8 7693-46-1**,
4-Nitrophenyl chloroformate **41110-63-8 63976-06-7**
102674-58-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

RE.CNT 104 THERE ARE 104 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Abbas, S; Sialic Acids Proc Japan-German Symp Berlin 1988, P22
(2) Akker, F; Protein Sci 1996, V5(6), P1184
(3) Altman, D; Practical Statistics for Medical Research, 1st ed 1991, P179
(4) Alvarez; US 5885577 1999 HCAPLUS
(5) Amvam-Zollo; Carbohy Res 1986, V150, P199 HCAPLUS
(6) Anon; WO 9308209 1993 HCAPLUS
(7) Anon; WO 9510296 1995
(8) Anon; WO 9748711 1997 HCAPLUS
(9) Anon; WO 9826662 1998 HCAPLUS
(10) Aoi, K; Marcomolecules 1995, V28, P5391 HCAPLUS
(11) Aqvist, J; J Biol Chem 1995, V270(17), P9978 MEDLINE
(12) Aqvist, J; Protein Eng 1994, V7(3), P385 MEDLINE
(13) Armstrong; US 5620858 1997 HCAPLUS
(14) Armstrong; US 5679653 1997 HCAPLUS
(15) Armstrong; Infect Immun 1987, V55, P1294 HCAPLUS
(16) Armstrong; J Infect Dis 1991, V164, P1160 HCAPLUS
(17) Ashton, P; Angewandete Chemie Int Ed Engl 1997, V36(7), P732 HCAPLUS
(18) Boyd; Nephron 1989, V51, P207 MEDLINE
(19) Brunton, J; The Bacteria, A Treatise on Structure and Function 1990, V11, P377
(20) Bundle; US 5962423 1999 HCAPLUS
(21) Calderwood; Proc Natl Acad Sci (USA) 1987, V84, P4364
(22) Calva, E; Gene 1989, V75, P243 HCAPLUS
(23) Chernyak, Y; Carbo Res 1984, V128, P269
(24) Cimolai; The Journal of Pediatrics 1990, V117, P676
(25) Cohen; J Biol Chem 1987, V262, P17088 HCAPLUS
(26) Cox; Carbohy Res 1978, V62, P245 HCAPLUS
(27) Dahmen, J; Carboh Res 1983, V118, P292 HCAPLUS
(28) Dahmen, J; Carboh Res 1984, V127, P15 HCAPLUS
(29) Degrandis; J Biol Chem 1989, V264, P12520 HCAPLUS
(30) Dey, I; J Biomol Struct 1999, V16(4), P891 HCAPLUS
(31) Ekborg, G; Carboh Res 1982, V110, P55 HCAPLUS
(32) Fernandez-Santana, V; J Carboh Chem 1989, V8(3), P531 HCAPLUS
(33) Frechet; US 5041516 1991 HCAPLUS
(34) Fugedi, P; Glycoconjugate J 1987, V4, P97 HCAPLUS
(35) Gannon; J Gen Microbiol 1990, V136, P1125 HCAPLUS
(36) Garegg, P; Carboh Res 1985, V136, P207 HCAPLUS

(37) Garegg, P; Carboh Res 1985, V137, P270 HCAPLUS
(38) Gozzini; US 5807971 1998 HCAPLUS
(39) Hansen; J Am Chem Soc 1997, V119, P6974 HCAPLUS
(40) Hansson, T; J Computer-Aided Mole Design 1998, V12, P27 HCAPLUS
(41) Hansson, T; Prot Eng 1995, V8(11), P1137 HCAPLUS
(42) Head, S; FEMS Microbiol Lett 1988, V51, P211 HCAPLUS
(43) Head, S; Infect Immunol 1990, V58, P1532 HCAPLUS
(44) Hohenester, E; J Mol Biol 1997, V269, P570 HCAPLUS
(45) Hol, W; Handbook of Natural Toxins 1995, V8, P185 HCAPLUS
(46) Ito; Microb Pathog 1990, V8, P47 HCAPLUS
(47) Jacewicz; J Exp Med 1986, V163, P1391 HCAPLUS
(48) Jackson; Microb Pathog 1987, V2, P147 HCAPLUS
(49) Jacquinet; J C S Perkin 1981, VI, P326
(50) Kameyama; Carboh Res 1991, V209, Pc1 HCAPLUS
(51) Karmali; J Clin Microbiol 1985, V22, P614 MEDLINE
(52) Koike, H; Carbohydr Res 1987, V163, P189
(53) Kolb, H; Bioorganic & Medicinal Chemistry Lett 1997, V7(20), P2629 HCAPLUS
(54) Kolb, H; Chem Eur J 1997, V3(10), P1571 HCAPLUS
(55) Lee; Carboh Res 1974, V37, P193 HCAPLUS
(56) Lemieux; US 4137401 1979 HCAPLUS
(57) Lemieux; US 4238473 1980 HCAPLUS
(58) Lemieux; US 4362720 1982 HCAPLUS
(59) Lemieux; J Am Chem Soc 1975, V97, P4076 HCAPLUS
(60) Lindberg; J Biol Chem 1987, V262, P1779 HCAPLUS
(61) Ling; Structure of the Shiga-like Toxin I B-Pentamer Complexed with an Analogue of Its Receptor Gb3, 1998, V37, P1777 HCAPLUS
(62) Lingwood; J Biol Chem 1987, V262, P8834 HCAPLUS
(63) Margerum; US 5834020 1998 HCAPLUS
(64) Merritt, E; Current Opinions in Structural Biology LTD 1995, V5(2), P165 HCAPLUS
(65) Merritt, E; Molecular Microbiology 1994, V13(4), P745 HCAPLUS
(66) Merritt, E; Protein Science 1994, V3, P166 HCAPLUS
(67) Merritt, E; Protein Science 1997, V6, P1516 HCAPLUS
(68) Nilsson; Bioconj Chem 1997, V8(4), P466 HCAPLUS
(69) Nyholm; Chem and Biol 1996, V3, P263 HCAPLUS
(70) Okamoto; Tetrahedron 1990, V47, P5835
(71) Oku; Microb Pathog 1989, V6, P113 HCAPLUS
(72) Paulsen, H; Angew Chem Int Ed Eng 1982, V21, P155
(73) Paulsen, H; Carbohydr Res 1982, V104, P195 HCAPLUS
(74) Pickett, C; J Bacteriol 1987, V169(11), P5180 HCAPLUS
(75) Pickett, C; J Bacteriol 1989, V171(9), P4945 HCAPLUS
(76) Rana, S; Carboh Res 1981, V91, P149 HCAPLUS
(77) Ratcliffe; US 5079353 1992 HCAPLUS
(78) Roboson; J Petitur 1990, V117, P675
(79) Roy, R; Polymer News 1996, V21(7), P226 HCAPLUS
(80) Samuel; Infect Immunol 1990, V58, P611 HCAPLUS
(81) Schaubach, R; Lievigs Am Chem 1991, P607 HCAPLUS
(82) Schmidt, R; Angew Chem Int Ed Eng 1986, V25, P212
(83) Schmitt, C; Infect Immun 1991, V59, P1065 HCAPLUS
(84) Schriemer, D; Angew Chem Int Ed 1998, V37(24), P3383 HCAPLUS
(85) Scotland, S; Lancet 1991, Vii, P885
(86) Shakhnovich; US 5854992 1998
(87) Simanek, E; Chem Rev 1998, V93, P833
(88) Sixma, T; J Mol Biol 1993, V230, P890 HCAPLUS
(89) Sixma, T; Nature 1991, V351, P371 HCAPLUS
(90) Sixma, T; Nature 1992, V355, P561 HCAPLUS
(91) Stehle, T; Naturel 1994, V369, P160 HCAPLUS
(92) Stehle, T; Structure 1996, V4(2), P165 HCAPLUS
(93) Stehle, T; Structure 1996, V4(2), P183 HCAPLUS
(94) Stein, P; Nature 1992, V335, P748
(95) Strockbine, N; J Bacterial 1988, V170, P1116 HCAPLUS
(96) Tomalia; US 5527524 1996 HCAPLUS
(97) Tomalia; US 5714166 1998 HCAPLUS

(98) Von Itzstein, M; Nature 1993, V363, P418 HCAPLUS
(99) Waddell, T; Biochem Biophys Res Comm 1988, V152, P674 HCAPLUS
(100) Waddell, T; Proc Natl Acad Sci (USA) 1990, V87, P7898 HCAPLUS
(101) Watson, K; Biochemistry 1994, V33, P5745 HCAPLUS
(102) Weinstein, D; Cloning and Sequencing of a Shiga-Like Toxin Type II Variant from an Escherichia coli Strain Responsible for Edema Disease of Swine, 1988, V170, P4223 HCAPLUS
(103) Wong, C; J Am Chem Soc 1997, V119, P8152 HCAPLUS
(104) Zanini, D; J Am Chem Soc 1997, V119(9), P2088 HCAPLUS

IT **258873-66-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)
RN 258873-66-4 HCAPLUS
CN Carbamic acid, [.beta.-D-glucopyranose-1,2,3,4,6-penta-O-ylpentakis[3,1-propanediylthio(1-oxo-2,1-ethanediyl)imino-2,1-ethanediylimino(3,4-dioxo-1-cyclobutene-2,1-diyl)imino-8,1-octanediyliminocarbonyloxy-3,1,2-propanetriyl]]decakis-, decaester with methyl O-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-2-O-(2-hydroxyethyl)-.beta.-D-galactopyranosyl-(1.fwdarw.4)-.beta.-D-glucopyranoside (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **79-06-1D**, Acrylamide, derivs. **574-93-6D**, Phthalocyanine, derivs. **12619-70-4D**, Cyclodextrin, derivs. **13117-26-5D**, derivs. **54832-51-8D**, derivs. **66580-68-5D**, derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)
RN 79-06-1 HCAPLUS
CN 2-Propenamide (9CI) (CA INDEX NAME)



RN 574-93-6 HCAPLUS
CN 29H,31H-Phthalocyanine (9CI) (CA INDEX NAME)



RN 12619-70-4 HCAPLUS
CN Cyclodextrin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 13117-26-5 HCAPLUS
CN D-Galactose, 4-O-.alpha.-D-galactopyranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 54832-51-8 HCAPLUS
CN D-Glucose, O-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 66580-68-5 HCAPLUS
CN D-Glucose, O-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-.beta.-D-galactopyranosyl-(1.fwdarw.4)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **58-85-5 9013-20-1**, Streptavidin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(label; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)
RN 58-85-5 HCAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanoic acid, hexahydro-2-oxo-, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 9013-20-1 HCAPLUS
CN Streptavidin (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **244076-91-3P 244076-92-4P 244076-93-5P**
244076-96-8P 244076-97-9P 244076-98-0P
244076-99-1P 244077-00-7P 244077-01-8P
244077-02-9P 244077-03-0P 244077-04-1P
244077-05-2P 244077-06-3P 244077-07-4P
244077-08-5P 244077-09-6P 258857-10-2P
258857-11-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)
RN 244076-91-3 HCAPLUS
CN D-Glucopyranose, 4-O-(3,4,6-tri-O-acetyl-2-O-2-propenyl-.beta.-D-galactopyranosyl)-, tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244076-92-4 HCAPLUS
CN .alpha.-D-Glucopyranosyl chloride, 4-O-(3,4,6-tri-O-acetyl-2-O-2-propenyl-.beta.-D-galactopyranosyl)-, triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 244076-93-5 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl 4-O-(2-O-2-propenyl-.beta.-D-galactopyranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 244076-96-8 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl 2,3,6-tris-O-(phenylmethyl)-4-O-[3-O-(phenylmethyl)-2-O-2-propenyl-.beta.-D-galactopyranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 244076-97-9 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl 4-O-[6-O-benzoyl-3-O-(phenylmethyl)-2-O-2-propenyl-.beta.-D-galactopyranosyl]-2,3,6-tris-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 244076-98-0 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl O-2,3,4,6-tetrakis-O-(phenylmethyl)-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-6-O-benzoyl-3-O-(phenylmethyl)-2-O-2-propenyl-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2,3,6-tris-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244076-99-1 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl O-2,3,4,6-tetrakis-O-(phenylmethyl)-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-3-O-(phenylmethyl)-2-O-2-propenyl-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2,3,6-tris-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 244077-00-7 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl O-2,3,4,6-tetrakis-O-(phenylmethyl)-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-3,6-bis-O-(phenylmethyl)-2-O-2-propenyl-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2,3,6-tris-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 244077-01-8 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl O-2,3,4,6-tetrakis-O-(phenylmethyl)-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-2-O-(2-hydroxyethyl)-3,6-bis-O-(phenylmethyl)-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2,3,6-tris-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 244077-02-9 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl O-2,3,4,6-tetrakis-O-(phenylmethyl)-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-2-O-[2-[[(4-nitrophenoxy)carbonyl]oxy]ethyl]-3,6-bis-O-(phenylmethyl)-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2,3,6-tris-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 2-A



RN 244077-03-0 HCAPLUS
CN .beta.-D-Glucopyranoside, 2',2''''-O-[(2-hydroxy-1,3-propanediyl)bis(iminocarbonyloxy-2,1-ethanediyl)]bis[methyl O-2,3,4,6-tetrakis-O-(phenylmethyl)-.beta.-D-galactopyranosyl-(1.fwdarw.4)-O-3,6-bis-O-(phenylmethyl)-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2,3,6-tris-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 1-B



PAGE 2-A





PAGE 2-B



RN 244077-04-1 HCAPLUS
CN .beta.-D-Glucopyranoside, 2',2''''-O-[[2-[[(4-nitrophenoxy)carbonyl]oxy]-1,3-propanediyl]bis(iminocarbonyloxy-2,1-ethanediyl)]bis[methyl O-2,3,4,6-tetrakis-O-(phenylmethyl)-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-3,6-bis-O-(phenylmethyl)-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2,3,6-tris-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



RN 244077-05-2 HCAPLUS
CN .beta.-D-Glucopyranoside, 2',2''''-O-[[2-[[[(8-aminooctyl)amino]carbonyl]oxy]-1,3-propanediyl]bis(iminocarbonyloxy-2,1-ethanediyl)]bis[methyl O-2,3,4,6-tetrakis-O-(phenylmethyl)-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-3,6-bis-O-(phenylmethyl)-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2,3,6-tris-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 2-A









PAGE 2-B

OMe

Ph

PAGE 3-A



PAGE 3-B

Ph

RN 244077-06-3 HCAPLUS

CN .beta.-D-Glucopyranoside, 2',2''''-O-[[2-[[[(8-aminooctyl)amino]carbonyl]oxy]-1,3-propanediyl]bis(iminocarbonyloxy-2,1-ethanediyl)]bis[methyl O-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-.beta.-D-galactopyranosyl-(1.fwdarw.4)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 1-B



PAGE 2-A

PAGE 2-B

RN 244077-07-4 HCAPLUS
CN .beta.-D-Glucopyranoside, 2',2''''-O-[[2-[[[[8-[(2-ethoxy-3,4-dioxo-1-cyclobuten-1-yl)amino]octyl]amino]carbonyl]oxy]-1,3-propanediyl]bis(iminocarbonyloxy-2,1-ethanediyl)]bis[methyl O-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-.beta.-D-galactopyranosyl-(1.fwdarw.4)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 2-A



PAGE 2-B



RN 244077-08-5 HCAPLUS
CN Acetic acid, [[3-[[2,3,4,6-tetrakis-O-[3-[(2-methoxy-2-oxoethyl)thio]propyl]-.beta.-D-glucopyranosyl]oxy]propyl]thio]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244077-09-6 HCAPLUS
CN Acetamide, N-(2-aminoethyl)-2-[[3-[[2,3,4,6-tetrakis-O-[3-[[2-[(2-aminoethyl)amino]-2-oxoethyl]thio]propyl]-.beta.-D-

glucopyranosyl]oxy]propyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 258857-10-2 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl 4-O-[4,6-O-(phenylmethylene)-2-O-2-propenyl-.beta.-D-galactopyranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258857-11-3 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl 2,3,6-tris-O-(phenylmethyl)-4-O-[3-O-(phenylmethyl)-4,6-O-(phenylmethylene)-2-O-2-propenyl-.beta.-D-

galactopyranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **98-88-4**, Benzoyl chloride **100-39-0 106-95-6**, Allyl bromide, reactions **107-15-3**, 1,2-Ethanediamine, reactions **373-44-4**, 1,8-Octanediamine **616-29-5**, 1,3-Diamino-2-hydroxypropane **1125-88-8 2365-48-2**, Methyl thioglycolate **5231-87-8 7693-46-1**, 4-Nitrophenyl chloroformate **41110-63-8 63976-06-7** **102674-58-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

RN 98-88-4 HCAPLUS
CN Benzoyl chloride (8CI, 9CI) (CA INDEX NAME)



RN 100-39-0 HCAPLUS
CN Benzene, (bromomethyl)- (9CI) (CA INDEX NAME)



RN 106-95-6 HCAPLUS
CN 1-Propene, 3-bromo- (9CI) (CA INDEX NAME)



RN 107-15-3 HCAPLUS
CN 1,2-Ethanediamine (9CI) (CA INDEX NAME)



RN 373-44-4 HCAPLUS

CN 1,8-Octanediamine (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 616-29-5 HCAPLUS
CN 2-Propanol, 1,3-diamino- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 1125-88-8 HCAPLUS
CN Benzene, (dimethoxymethyl)- (9CI) (CA INDEX NAME)



RN 2365-48-2 HCAPLUS
CN Acetic acid, mercapto-, methyl ester (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 5231-87-8 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3,4-diethoxy- (9CI) (CA INDEX NAME)



RN 7693-46-1 HCAPLUS
CN Carbonochloridic acid, 4-nitrophenyl ester (9CI) (CA INDEX NAME)



RN 41110-63-8 HCAPLUS
CN .alpha.-D-Galactopyranosyl chloride, 2,3,4,6-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 63976-06-7 HCAPLUS
CN .beta.-D-Glucopyranoside, 2-propenyl 2,3,4,6-tetra-O-2-propenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 102674-58-8 HCAPLUS
CN D-Glucose, 4-O-[6-O-(1-methoxy-1-methylethyl)-3,4-O-(1-methylethylidene)-.beta.-D-galactopyranosyl]-2,3:5,6-bis-O-(1-methylethylidene)-, dimethyl acetal (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L41 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2003 ACS
AN 2001:31361 HCAPLUS
DN 134:101139
TI Preparation of self-associating compounds and their aggregate bodies for use as medicaments
IN **Bovin, Nikolai Vladimirovich; Tusikov, Alexandr Borisovich; Chinarev, Alexandr Alexandrovich; Dicusar, Mariya Alexandrovna; Gambariyan, Alexandra Sergeevna;**

Marinina, Valentina Petrovna
PA Syntesome Gesellschaft fur Medizinische Biochemie m.b.H., Germany
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DT **Patent**
LA German
IC ICM A61K047-48
CC 33-4 (Carbohydrates)
Section cross-reference(s): 34, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001002018	A2	20010111	WO 2000-EP6139	20000630 <--
WO 2001002018	A3	20020314		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CU, CZ, DE, DK, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19930177	A1	20010111	DE 1999-19930177	19990630 <--
EP 1223984	A2	20020724	EP 2000-949235	20000630 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003503465	T2	20030128	JP 2001-507508	20000630 <--
PRAI DE 1999-19930177	A	19990630 <--		
WO 2000-EP6139	W	20000630 <--		

AB Title compds., [e.g., {.alpha.-Neu5Ac-OCH2-4-C6H4-NHC(O)CH2NHC(O)(CH2)4C(O)(NHCH2C(O))0-7NHCH2}4C], in which the terminal portion of each arm may contain fragments capable of cellular receptor blocking, antibiotic, or therapeutic action, capable of forming self-aggregates, were prepd. for use as drug-delivery or diagnostic agents. The tetrahedral core was synthesized from {H2NCH2}4C using BOC-peptide coupling chem. The terminal units were prepd. from tetra-O-acetyl-5-acetylneuraminic acid Me ester derivs., 5-acetylneuraminic acid .alpha.-2.fwdarw.3-B-D-GalP-(1.fwdarw.4)-.beta.-D-GluP-NHC(O)CH2NH2, or .alpha.-D-GalP-(1.fwdarw.3)-.beta.-D-GalP-O-(CH2)3NH2 derivs. In a test of inhibition of viral cell adhesion, using influenza virus, {.alpha.-Neu5Ac-OCH2-4-C6H4-NHC(O)CH2NHC(O)(CH2)4C(O)(NH(CH2)5C(O))3(NHCH2C(O))5NHCH2}4C had relative activity (to Neu5Ac-.alpha.-CH2Ph) of 2500:1.

ST oligosaccharide peptide conjugate prepn aggregating drug delivery
IT Neoplasm
(metastasis; prepn. of self-assocg. compds. and their aggregate bodies for use as medicaments)
IT Autoimmune disease
Coupling reaction
Drug delivery systems
Infection
Inflammation
Influenza virus
Self-association
(prepn. of self-assocg. compds. and their aggregate bodies for use as medicaments)
IT Transplant and Transplantation
(rejection; prepn. of self-assocg. compds. and their aggregate bodies for use as medicaments)
IT Wound healing
(selectin-facilitated; prepn. of self-assocg. compds. and their aggregate bodies for use as medicaments)

IT **318286-47-4P 318286-49-6P 318286-51-0P**
318286-53-2P 318286-55-4P 318286-65-6DP,
self-aggregates **318507-77-6P 318508-09-7P**
318508-48-4P 318508-50-8P 318508-52-0P
318508-53-1DP, self-aggregates **318508-54-2DP**,
self-aggregates **318508-57-5DP**, self-aggregates
318508-58-6DP, self-aggregates **318509-04-5P**
318509-46-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of self-assocg. compds. and their aggregate bodies for use as medicaments)

IT **3392-07-2 29248-48-4 51513-80-5**
53546-95-5 137125-82-7 201667-63-2
205753-10-2 318286-06-5 318286-10-1
318286-61-2 318286-67-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of self-assocg. compds. and their aggregate bodies for use as medicaments)

IT **14302-75-1P 32564-25-3P 205753-09-9P**
226408-84-0P 318285-90-4P 318285-93-7P
318285-95-9P 318286-08-7P 318286-16-7P
318286-19-0P 318286-21-4P 318286-23-6P
318286-25-8P 318286-27-0P 318286-29-2P
318286-31-6P 318286-33-8P 318286-35-0P
318286-37-2P 318286-41-8P 318286-43-0P
318286-57-6P 318286-59-8P 318286-69-0P
318510-95-1P 318511-00-1P 318511-08-9P
318511-10-3P 318511-11-4P 318511-17-0P
318511-35-2P 318511-41-0P 318511-44-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of self-assocg. compds. and their aggregate bodies for use as medicaments)

IT **318285-97-1P 318285-99-3P 318286-01-0P**
318286-03-2P 318286-45-2P 318286-63-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of self-assocg. compds. and their aggregate bodies for use as medicaments)

IT **318286-47-4P 318286-49-6P 318286-51-0P**
318286-53-2P 318286-55-4P 318286-65-6DP,
self-aggregates **318507-77-6P 318508-09-7P**
318508-48-4P 318508-50-8P 318508-52-0P
318508-53-1DP, self-aggregates **318508-54-2DP**,
self-aggregates **318508-57-5DP**, self-aggregates
318508-58-6DP, self-aggregates **318509-04-5P**
318509-46-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of self-assocg. compds. and their aggregate bodies for use as medicaments)

RN 318286-47-4 HCAPLUS

CN .alpha.-Neuraminic acid, 2,2'-O-[[15,15-bis[[[[[6-[[2-[[4-[[(N-acetyl-.alpha.-neuraminosyl)oxy]methyl]phenyl]amino]-2-oxoethyl]amino]-1,6-dioxohexyl]amino]acetyl]amino]methyl]-1,4,9,12,18,21,16,29-octaoxo-3,10,13,17,20,27-hexaazanonacosane-1,29-diyl]bis(imino-4,1-phenylenemethylene)]bis[N-acetyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C

PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-A



RN 318286-49-6 HCAPLUS
CN Glycine, N-[6-[[2-[[4-[[(N-acetyl-.alpha.-neuraminosyl)oxy]methyl]phenyl]amino]-2-oxoethyl]amino]-1,6-dioxohexyl]glycyl-, 2,2',2'',2'''-tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-A



PAGE 3-B



RN 318286-51-0 HCAPLUS
CN Glycine, N-[6-[[2-[[4-[[(N-acetyl-.alpha.-neuraminosyl)oxy]methyl]phenyl]amino]-2-oxoethyl]amino]-1,6-dioxohexyl]glycylglycyl-, 3,3',3'',3'''-tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



PAGE 2-C



PAGE 3-A



PAGE 3-B



RN 318286-53-2 HCAPLUS
CN Glycine, N-[6-[[2-[[4-[[(N-acetyl-.alpha.-neuraminosyl)oxy]methyl]phenyl]amino]-2-oxoethyl]amino]-1,6-dioxohexyl]glycylglycylglycyl-, 4,4',4'',4'''-tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D





PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 3-A



PAGE 3-B



RN 318286-55-4 HCAPLUS
CN Glycine, N-[6-[[2-[[4-[[(N-acetyl-.alpha.-neuraminosyl)oxy]methyl]phenyl]amino]-2-oxoethyl]amino]-1,6-dioxohexyl]glycylglycylglycylglycyl-, 5,5',5'',5'''-tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



PAGE 2-A



PAGE 2-D



PAGE 3-A



PAGE 3-B



RN 318286-65-6 HCAPLUS
CN Glycinamide, 6,6'-(1,4-butanediyl)bis[N-[6-[[2-[[4-[[(N-acetyl-.alpha.-neuraminosyl)oxy]methyl]phenyl]amino]-2-oxoethyl]amino]-1,6-dioxohexyl]glycylglycylglycylglycylglycyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



RN 318507-77-6 HCAPLUS
CN Glycine, N-[6-[[6-[[6-[[2-[[4-[[(N-acetyl-.alpha.-neuraminosyl)oxy]methyl]phenyl]amino]-2-oxoethyl]amino]-1,6-dioxohexyl]amino]-1-oxohexyl]amino]-1-oxohexyl]glycylglycylglycylglycyl-, 5,5',5'',5'''-tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 318508-09-7 HCAPLUS
CN Glycine, N-[30-[[4-[[(N-acetyl-.alpha.-neuraminosyl)oxy]methyl]phenyl]amino]-1,8,15,22,27,30-hexaoxo-7,14,21,28-tetraazatriacont-1-yl]glycylglycylglycylglycyl-, 5,5',5'',5'''-tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 318508-48-4 HCAPLUS
CN Glycine, N-[6-[[6-[[2-[[4-[[(N-acetyl-.alpha.-neuraminosyl)oxy]methyl]phenyl]amino]-2-oxoethyl]amino]-6-oxohexyl]amino]-1,6-dioxohexyl]glycylglycylglycylglycyl-, 5,5',5'',5'''-tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 318508-50-8 HCAPLUS

CN Glycine, N-[6-[[6-[[6-[[2-[[4-[[(N-acetyl-.alpha.-neuraminosyl)oxy]methyl]phenyl]amino]-2-oxoethyl]amino]-6-oxohexyl]amino]-6-oxohexyl]amino]-1,6-dioxohexyl]glycylglycylglycylglycyl-, 5,5',5'',5'''-tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 318508-52-0 HCAPLUS
CN Glycine, N-[30-[[4-[[(N-acetyl-.alpha.-neuraminosyl)oxy]methyl]phenyl]amino]-1,6,13,20,27,30-hexaoxo-7,14,21,28-tetraazatriacont-1-yl]glycylglycylglycylglycyl-, 5,5',5'',5'''-tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 318508-53-1 HCAPLUS
CN Glycine, N-[6-[[2-[[4-[[(N-acetyl-.alpha.-neuraminosyl)oxy]methyl]phenyl]amino]-2-oxoethyl]amino]-1,6-dioxohexyl]glycylglycylglycylglycylglycylglycylglycyl-, 7,7',7'',7'''-tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 318508-54-2 HCAPLUS
CN Glycine, N-[31-[(3-O-.alpha.-D-galactopyranosyl-.beta.-D-galactopyranosyl)oxy]-1,8,15,22,27-pentaoxo-7,14,21,28-tetraazahentriacont-1-yl]glycylglycylglycylglycyl-, tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 318508-57-5 HCAPLUS
CN Glycine, N-[6-[[2-[[O-(N-acetyl-4,7,8,9-tetra-O-acetyl-.alpha.-neuraminosyl)-(2.fwdarw.3)-O-.beta.-D-galactopyranosyl-(1.fwdarw.4)-.beta.-D-glucopyranosyl]amino]-2-oxoethyl]amino]-1,6-dioxohexyl]glycylglycylglycylglycyl-, 5,5',5'',5'''-tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 318508-58-6 HCAPLUS
CN Glycine, N-[6-[[2-[[O-(N-acetyl-4,7,8,9-tetra-O-acetyl-.alpha.-neuraminosyl)-(2.fwdarw.3)-O-.beta.-D-galactopyranosyl-(1.fwdarw.4)-.beta.-D-glucopyranosyl]amino]-2-oxoethyl]amino]-1,6-dioxohexyl]glycylglycylglycylglycylglycylglycylglycyl-, 7,7',7'',7'''-tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 318509-04-5 HCAPLUS
CN Glycine, N-[6-[[3-[[O-(N-acetyl-4,7,8,9-tetra-O-acetyl-.alpha.-neuraminosyl)-(2.fwdarw.6)-O-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2-(acetylamino)-2-deoxy-.beta.-D-glucopyranosyl]oxy]propyl]amino]-1,6-dioxohexyl]glycylglycylglycylglycylglycylglycylglycyl-, 7,7',7'',7'''-tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 318509-46-5 HCAPLUS
CN Glycine, N-[6-[[6-[[6-[[3-[[O-(N-acetyl-4,7,8,9-tetra-O-acetyl-.alpha.-neuraminosyl)-(2.fwdarw.6)-O-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2-(acetylamino)-2-deoxy-.beta.-D-glucopyranosyl]oxy]propyl]amino]-1,6-dioxohexyl]amino]-1-oxohexyl]amino]-1-oxohexyl]glycylglycylglycylglycylglycylglycylglycyl-, 7,7',7'',7'''-tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **3392-07-2 29248-48-4 51513-80-5 53546-95-5 137125-82-7 201667-63-2**

205753-10-2 318286-06-5 318286-10-1
318286-61-2 318286-67-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of self-assocg. compds. and their aggregate bodies for use as medicaments)

RN 3392-07-2 HCAPLUS
CN Carbamic acid, [2-[(2,5-dioxo-1-pyrrolidinyl)oxy]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 29248-48-4 HCAPLUS
CN 2,5-Pyrrolidinedione, 1-[[N-[(1,1-dimethylethoxy)carbonyl]glycylglycyl]oxy]- (9CI) (CA INDEX NAME)



RN 51513-80-5 HCAPLUS
CN Carbamic acid, [6-[(2,5-dioxo-1-pyrrolidinyl)oxy]-6-oxohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 53546-95-5 HCAPLUS
CN Hexanoic acid, 6-[[(1,1-dimethylethoxy)carbonyl]amino]-, 4-nitrophenyl ester (9CI) (CA INDEX NAME)



RN 137125-82-7 HCAPLUS
CN .alpha.-Neuraminic acid, N-acetyl-2-O-[[4-[[[[(1,1-

dimethylethoxy)carbonyl]amino]acetyl]amino]phenyl]methyl]-, methyl ester, 4,7,8,9-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 201667-63-2 HCAPLUS
CN .beta.-D-Galactopyranoside, 3-aminopropyl 3-O-.alpha.-D-galactopyranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205753-10-2 HCAPLUS
CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]glycylglycyl-, tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 318286-06-5 HCAPLUS
CN Acetamide, N-[O-(N-acetyl-4,7,8,9-tetra-O-acetyl-.alpha.-neuraminosyl)-(2.fwdarw.3)-O-.beta.-D-galactopyranosyl-(1.fwdarw.4)-.beta.-D-glucopyranosyl]-2-amino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 318286-10-1 HCAPLUS
CN .alpha.-Neuraminic acid, N-acetyl-2-O-[[4-[(aminoacetyl)amino]phenyl]methyl]-, 4,7,8,9-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 318286-61-2 HCAPLUS
CN Glycinamide, 4,4'-(1,4-butanediyl)bis[glycylglycylglycyl-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



●2 HCl

PAGE 1-B



RN 318286-67-8 HCAPLUS
CN .beta.-D-Glucopyranoside, 3-aminopropyl O-(N-acetyl-4,7,8,9-tetra-O-acetyl-.alpha.-neuraminosyl)-(2.fwdarw.6)-O-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **14302-75-1P 32564-25-3P 205753-09-9P**
226408-84-0P 318285-90-4P 318285-93-7P
318285-95-9P 318286-08-7P 318286-16-7P
318286-19-0P 318286-21-4P 318286-23-6P
318286-25-8P 318286-27-0P 318286-29-2P
318286-31-6P 318286-33-8P 318286-35-0P
318286-37-2P 318286-41-8P 318286-43-0P
318286-57-6P 318286-59-8P 318286-69-0P
318510-95-1P 318511-00-1P 318511-08-9P
318511-10-3P 318511-11-4P 318511-17-0P
318511-35-2P 318511-41-0P 318511-44-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of self-assocg. compds. and their aggregate bodies for use as medicaments)

RN 14302-75-1 HCAPLUS
CN 1,3-Propanediamine, 2,2-bis(aminomethyl)-, tetrahydrochloride (8CI, 9CI) (CA INDEX NAME)



● 4 HCl

RN 32564-25-3 HCAPLUS
CN Hexanedioic acid, bis(4-nitrophenyl) ester (9CI) (CA INDEX NAME)



RN 205753-09-9 HCAPLUS
CN 2,5,9,12-Tetraazatridecanedioic acid, 7,7-bis[[[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]amino]methyl]-4,10-dioxo-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 226408-84-0 HCAPLUS
CN Hexanoic acid, 6-[[3-[(3-O-.alpha.-D-galactopyranosyl-.beta.-D-galactopyranosyl)oxy]propyl]amino]-6-oxo-, 4-nitrophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 318285-90-4 HCAPLUS
CN .alpha.-Neuraminic acid, N-acetyl-2-O-[[4-[[[[6-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxohexyl]amino]acetyl]amino]phenyl]methyl]-, methyl ester, 4,7,8,9-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—OBu-t

RN 318285-93-7 HCAPLUS
CN .alpha.-Neuraminic acid, N-acetyl-2-O-[[4-[(20,20-dimethyl-1,4,11,18-tetraoxo-19-oxa-3,10,17-triazaheneicos-1-yl)amino]phenyl]methyl]-, methyl ester, 4,7,8,9-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 318285-95-9 HCAPLUS
CN .alpha.-Neuraminic acid, N-acetyl-2-O-[[4-[(27,27-dimethyl-1,4,11,18,25-pentaoxo-26-oxa-3,10,17,24-tetraazaoctacos-1-yl)amino]phenyl]methyl]-, methyl ester, 4,7,8,9-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 318286-08-7 HCAPLUS
CN Hexanoic acid, 6-[[2-[[O-(N-acetyl-4,7,8,9-tetra-O-acetyl-.alpha.-neuraminosyl)-(1.fwdarw.3)-O-.beta.-D-galactopyranosyl-(1.fwdarw.4)-.beta.-D-glucopyranosyl]amino]-2-oxoethyl]amino]-6-oxo-, 1-(4-nitrophenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 318286-16-7 HCAPLUS
CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]glycylglycylglycylglycyl-, tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 318286-19-0 HCAPLUS
CN Glycine, glycyl-, tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine, tetrahydrochloride (9CI) (CA INDEX NAME)



●4 HCl

RN 318286-21-4 HCAPLUS
CN Glycine, glycyl-, tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)



RN 318286-23-6 HCAPLUS
CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]glycylglycylglycyl-, tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 318286-25-8 HCAPLUS
CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]glycylglycylglycylglycylglycylglycylglycyl-, tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D

—OBu-t

RN 318286-27-0 HCAPLUS
CN Glycine, N-(6-amino-1-oxohexyl)glycylglycylglycylglycyl-, tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine, tetrahydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 4 HCl

PAGE 1-B



PAGE 1-C



RN 318286-29-2 HCAPLUS
CN Glycine, N-(6-amino-1-oxohexyl)glycylglycylglycylglycyl-, tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B





PAGE 1-C



RN 318286-31-6 HCAPLUS
CN Glycine, N-[6-[(6-amino-1-oxohexyl)amino]-1-oxohexyl]glycylglycylglycylgly cyl-, tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine, tetrahydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 4 HCl

PAGE 1-B



PAGE 1-C



RN 318286-33-8 HCAPLUS
CN Glycine, N-[6-[(6-amino-1-oxohexyl)amino]-1-oxohexyl]glycylglycylglycylgly cyl-, tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA

INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 318286-35-0 HCAPLUS
CN Glycine, N-[6-[[6-[(6-amino-1-oxohexyl)amino]-1-oxohexyl]amino]-1-oxohexyl]glycylglycylglycylglycyl-, tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine, tetrahydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 4 HCl

PAGE 1-B



PAGE 1-C



PAGE 1-D



RN 318286-37-2 HCAPLUS
CN Glycine, N-[6-[[6-[(6-amino-1-oxohexyl)amino]-1-oxohexyl]amino]-1-oxohexyl]glycylglycylglycylglycyl-, tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B





PAGE 1-C



PAGE 1-D



RN 318286-41-8 HCAPLUS
CN .alpha.-Neuraminic acid, 2,2'-O-[[12,12-bis[[[6-[[2-[[4-[[(N-acetyl-4,7,8,9-tetra-O-acetyl-1-methyl-.alpha.-neuraminosyl)oxy]methyl]phenyl]amino]-2-oxoethyl]amino]-1,6-dioxohexyl]amino]methyl]-1,4,9,15,20,23-hexaoxo-3,10,14,21-tetraazatricosane-1,23-diyl]bis(imino-4,1-phenylenemethylene)]bis[N-acetyl-, dimethyl ester, 4,4',7,7',8,8',9,9'-octaacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 3-B

RN 318286-43-0 HCAPLUS
CN .alpha.-Neuraminic acid, 2,2'-O-[[15,15-bis[[[[[6-[[2-[[4-[[(N-acetyl-4,7,8,9-tetra-O-acetyl-1-methyl-.alpha.-neuraminosyl)oxy]methyl]phenyl]amino]-2-oxoethyl]amino]-1,6-dioxohexyl]amino]acetyl]amino]methyl]-1,4,9,12,18,21,16,29-octaoxo-3,10,13,17,20,27-hexaazanonacosane-1,29-diyl]bis(imino-4,1-phenylenemethylene)]bis[N-acetyl-, dimethyl ester, 4,4',7,7',8,8',9,9'-octaacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



PAGE 2-B



PAGE 2-C



RN 318286-57-6 HCAPLUS
CN Glycine, glycylglycylglycylglycyl-, tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine, tetrahydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 4 HCl

PAGE 1-B



PAGE 1-C

RN 318286-59-8 HCAPLUS
CN Glycine, glycylglycylglycylglycylglycylglycyl-, tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine, tetrahydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



● 4 HCl

PAGE 1-B



PAGE 1-C



RN 318286-69-0 HCAPLUS
CN Hexanoic acid, 6-[[3-[[O-(N-acetyl-4,7,8,9-tetra-O-acetyl-.alpha.-neuraminosyl)-(2.fwdarw.6)-O-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2-(acetylamino)-2-deoxy-.beta.-D-glucopyranosyl]oxy]propyl]amino]-6-oxo-, 4-nitrophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 318510-95-1 HCAPLUS
CN Glycine, N-[6-[[2-[[4-[[(N-acetyl-4,7,8,9-tetra-O-acetyl-1-methyl-.alpha.-neuraminosyl)oxy]methyl]phenyl]amino]-2-oxoethyl]amino]-1,6-dioxohexyl]glycylglycylglycylglycyl-, tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 318511-00-1 HCAPLUS
CN Glycine, N-[6-[[2-[[4-[[(N-acetyl-4,7,8,9-tetra-O-acetyl-1-methyl-.alpha.-neuraminosyl)oxy]methyl]phenyl]amino]-2-oxoethyl]amino]-1,6-dioxohexyl]glycyl-, tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 318511-08-9 HCAPLUS
CN Glycine, N-[6-[[2-[[4-[[(N-acetyl-4,7,8,9-tetra-O-acetyl-1-methyl-.alpha.-neuraminosyl)oxy]methyl]phenyl]amino]-2-oxoethyl]amino]-1,6-dioxohexyl]glycylglycyl-, tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 318511-10-3 HCAPLUS
CN Glycine, N-[6-[[2-[[4-[[(N-acetyl-4,7,8,9-tetra-O-acetyl-1-methyl-.alpha.-neuraminosyl)oxy]methyl]phenyl]amino]-2-oxoethyl]amino]-1,6-dioxohexyl]glycylglycylglycyl-, tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 318511-11-4 HCAPLUS
CN Glycine, N-[6-[[6-[[6-[[2-[[4-[[(N-acetyl-4,7,8,9-tetra-O-acetyl-1-methyl-.alpha.-neuraminosyl)oxy]methyl]phenyl]amino]-2-oxoethyl]amino]-1,6-dioxohexyl]amino]-1-oxohexyl]amino]-1-oxohexyl]glycylglycylglycylglycyl-, tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 318511-17-0 HCAPLUS
CN Glycine, N-[30-[[4-[[(N-acetyl-4,7,8,9-tetra-O-acetyl-1-methyl-.alpha.-neuraminosyl)oxy]methyl]phenyl]amino]-1,8,15,22,27,30-hexaoxo-7,14,21,28-

tetraazatriacont-1-yl]glycylglycylglycylglycyl-, tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 318511-35-2 HCAPLUS
CN Glycine, N-[6-[[6-[[2-[[4-[[(N-acetyl-4,7,8,9-tetra-O-acetyl-1-methyl-.alpha.-neuraminosyl)oxy]methyl]phenyl]amino]-2-oxoethyl]amino]-6-oxohexyl]amino]-1,6-dioxohexyl]glycylglycylglycylglycyl-, tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 318511-41-0 HCAPLUS
CN Glycine, N-[6-[[6-[[6-[[2-[[4-[[(N-acetyl-4,7,8,9-tetra-O-acetyl-1-methyl-.alpha.-neuraminosyl)oxy]methyl]phenyl]amino]-2-oxoethyl]amino]-6-oxohexyl]amino]-6-oxohexyl]amino]-1,6-dioxohexyl]glycylglycylglycylglycyl-, tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 318511-44-3 HCAPLUS
CN Glycine, N-[30-[[4-[[(N-acetyl-4,7,8,9-tetra-O-acetyl-1-methyl-.alpha.-neuraminosyl)oxy]methyl]phenyl]amino]-1,6,13,20,27,30-hexaoxo-7,14,21,28-tetraazatriacont-1-yl]glycylglycylglycylglycyl-, tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **318285-97-1P 318285-99-3P 318286-01-0P**
318286-03-2P 318286-45-2P 318286-63-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of self-assocg. compds. and their aggregate bodies for use as medicaments)
RN 318285-97-1 HCAPLUS
CN .alpha.-Neuraminic acid, N-acetyl-2-O-[[4-[[[[6-(4-nitrophenoxy)-1,6-dioxohexyl]amino]acetyl]amino]phenyl]methyl]-, methyl ester, 4,7,8,9-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 318285-99-3 HCAPLUS

CN .alpha.-Neuraminic acid, N-acetyl-2-O-[[4-[[[[6-[[6-(4-nitrophenoxy)-1,6-dioxohexyl]amino]-1-oxohexyl]amino]acetyl]amino]phenyl]methyl]-, methyl ester, 4,7,8,9-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 318286-01-0 HCAPLUS

CN .alpha.-Neuraminic acid, N-acetyl-2-O-[[4-[[[[6-[[6-[[6-(4-nitrophenoxy)-1,6-dioxohexyl]amino]-1-oxohexyl]amino]-1-oxohexyl]amino]acetyl]amino]phenyl]methyl]-, methyl ester, 4,7,8,9-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 318286-03-2 HCAPLUS
CN .alpha.-Neuraminic acid, N-acetyl-2-O-[[4-[[30-(4-nitrophenoxy)-1,4,11,18,25,30-hexaoxo-3,10,17,24-tetraazatriacont-1-yl]amino]phenyl]methyl]-, methyl ester, 4,7,8,9-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 318286-45-2 HCAPLUS
CN .alpha.-Neuraminic acid, 2,2'-O-[[12,12-bis[[[6-[[2-[[4-[[(N-acetyl-.alpha.-neuraminosyl)oxy]methyl]phenyl]amino]-2-oxoethyl]amino]-1,6-dioxohexyl]amino]methyl]-1,4,9,15,20,23-hexaoxo-3,10,14,21-tetraazatricosane-1,23-diyl]bis(imino-4,1-phenylenemethylene)]bis[N-acetyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

PAGE 1-B



PAGE 2-A



PAGE 2-B



RN 318286-63-4 HCAPLUS
CN Glycinamide, 6,6'-(1,4-butanediyl)bis[glycylglycylglycylglycylglycyl-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



●2 HCl

PAGE 1-B



PAGE 1-C



L41 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2003 ACS
AN 2000:117249 HCAPLUS
DN 132:161232
TI Compounds, including saccharide compounds, for treatment of bacterial infections, and preparation thereof
IN Bundle, David R.; Kitov, Pavel; Read, Randy J.; Ling, Hong; Armstrong, Glen
PA The Governors of the University of Alberta, Can.
SO PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM G01N033-53
CC 1-5 (Pharmacology)
Section cross-reference(s): 33, 63
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2000008467	A2	20000217	WO 1999-CA725	19990806	
	WO 2000008467	A3	20000706			
	W: AU, CA, JP					
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
	US 5962423	A	19991005	US 1998-130495	19980807	
	US 6310043	B1	20011030	US 1999-317290	19990524	<--
	CA 2339198	AA	20000217	CA 1999-2339198	19990806	
	AU 9951450	A1	20000228	AU 1999-51450	19990806	
	AU 754331	B2	20021114			
	EP 1102779	A2	20010530	EP 1999-936219	19990806	
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
PRAI	US 1998-130495	A	19980807			
	US 1999-317290	A	19990524			
	WO 1999-CA725	W	19990806			

AB Compds. which bind to toxins assocd. with enteric bacterial infection, compns. including the compds., methods for the neutralization of toxins in a patient, and methods for the diagnosis of bacterial and viral infections are disclosed. Toxins which can be bound by the compds. include pentameric toxins, for example SLTs (shiga-like toxins), such as those from Salmonella, Campylobacter and other bacteria, verotoxins from E. coli, cholera toxin, Clostridium difficile toxins A and B, bacterial pili from enteropathogenic E. coli and enterotoxigenic E. coli and viral lectins, such as viral hemagglutinins. The compds. include a core mol. bound to a plurality of linker arms, which in turn are bound to a plurality of bridging moieties, which in turn are bound to at least one, and preferably, two or more ligands which bind to the toxin. Examples of suitable ligands include di- and for trisaccharide moieties. The di- or tri-saccharide moieties themselves are active in binding to the SLTs. The presence of a plurality of bridged dimers of the ligands is responsible for the increased binding affinity of the compds. relative to the ligands themselves. In one embodiment, the compds., when administered in a timely fashion to a patient suffering from enteric E. coli infection, inhibit progression of this infection into hemolytic uremic syndrome (HUS).

ST antibacterial bacterial toxin saccharide deriv prepn; bacteria virus infection diagnosis; Escherichia hemolytic uremic syndrome saccharide deriv

IT Toxins
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(B, Clostridium difficile; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Toxins
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(Shiga-like toxin I; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Toxins
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(Shiga-like toxin II; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Toxins
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(Shiga-like toxin; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Carbohydrates, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(aldaric acids; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Peptides, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(amino acids; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Infection
(bacterial, diagnosis; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Toxins
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(cholera; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Antibacterial agents
Campylobacter
Drug delivery systems
Salmonella
(compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Toxins
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Agglutinins and Lectins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Amino acids, biological studies
Disaccharides

Monosaccharides
Oligosaccharides, biological studies
Trisaccharides
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Escherichia coli
(enterotoxigenic; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Pilus
(from enteropathogenic E. coli; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Drug delivery systems
(injections; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Fluorescent substances
(label; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Enzymes, biological studies
Radionuclides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(label; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Drug delivery systems
(oral; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Intestinal bacteria
(pathogenic, pili from enteropathogenic E. coli; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Escherichia coli
(pili from enteropathogenic E. coli; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Alcohols, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(polyhydric; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Albumins, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(saccharide derivs.; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Toxins
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(toxin A, Clostridium difficile; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Clostridium difficile
(toxins A and B; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT Virus
(viral lectin; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT **258873-66-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT **79-06-1D**, Acrylamide, derivs. **574-93-6D**, Phthalocyanine, derivs. **12619-70-4D**, Cyclodextrin, derivs. **13117-26-5D**, derivs. **54832-51-8D**, derivs. **66580-68-5D**, derivs.

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT **58-85-5 9013-20-1**, Streptavidin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(label; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT **244076-91-3P 244076-92-4P 244076-93-5P**
244076-96-8P 244076-97-9P 244076-98-0P
244076-99-1P 244077-00-7P 244077-01-8P
244077-02-9P 244077-03-0P 244077-04-1P
244077-05-2P 244077-06-3P 244077-07-4P
244077-08-5P 244077-09-6P 258857-10-2P
258857-11-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT **98-88-4**, Benzoyl chloride **100-39-0 106-95-6**,
Allyl bromide, reactions **107-15-3**, 1,2-Ethanediamine, reactions
373-44-4, 1,8-Diaminooctane **616-29-5**,
1,3-Diamino-2-hydroxypropane **1125-88-8**, .alpha.,.alpha.-Dimethoxytoluene **2365-48-2**, Methyl thioglycolate
5231-87-8 7693-46-1, 4-Nitrophenyl chloroformate
41110-63-8 63976-06-7 102674-58-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

IT **258873-66-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

RN 258873-66-4 HCAPLUS
CN Carbamic acid, [.beta.-D-glucopyranose-1,2,3,4,6-penta-O-ylpentakis[3,1-propanediylthio(1-oxo-2,1-ethanediyl)imino-2,1-ethanediylimino(3,4-dioxo-1-cyclobutene-2,1-diyl)imino-8,1-octanediyliminocarbonyloxy-3,1,2-propanetriyl]]decakis-, decaester with methyl O-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-2-O-(2-hydroxyethyl)-.beta.-D-galactopyranosyl-(1.fwdarw.4)-.beta.-D-glucopyranoside (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT **79-06-1D**, Acrylamide, derivs. **574-93-6D**, Phthalocyanine, derivs. **12619-70-4D**, Cyclodextrin, derivs. **13117-26-5D**
, derivs. **54832-51-8D**, derivs. **66580-68-5D**, derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

RN 79-06-1 HCAPLUS
CN 2-Propenamide (9CI) (CA INDEX NAME)



RN 574-93-6 HCAPLUS

CN 29H,31H-Phthalocyanine (9CI) (CA INDEX NAME)



RN 12619-70-4 HCAPLUS
CN Cyclodextrin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 13117-26-5 HCAPLUS
CN D-Galactose, 4-O-.alpha.-D-galactopyranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 54832-51-8 HCAPLUS
CN D-Glucose, O-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 66580-68-5 HCAPLUS
CN D-Glucose, O-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-.beta.-D-galactopyranosyl-(1.fwdarw.4)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **58-85-5 9013-20-1**, Streptavidin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(label; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)
RN 58-85-5 HCAPLUS
CN 1H-Thieno[3,4-d]imidazole-4-pentanoic acid, hexahydro-2-oxo-, (3aS,4S,6aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 9013-20-1 HCAPLUS
CN Streptavidin (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **244076-91-3P 244076-92-4P 244076-93-5P**
244076-96-8P 244076-97-9P 244076-98-0P
244076-99-1P 244077-00-7P 244077-01-8P
244077-02-9P 244077-03-0P 244077-04-1P
244077-05-2P 244077-06-3P 244077-07-4P
244077-08-5P 244077-09-6P 258857-10-2P
258857-11-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)
RN 244076-91-3 HCAPLUS
CN D-Glucopyranose, 4-O-(3,4,6-tri-O-acetyl-2-O-2-propenyl-.beta.-D-galactopyranosyl)-, tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244076-92-4 HCAPLUS
CN .alpha.-D-Glucopyranosyl chloride, 4-O-(3,4,6-tri-O-acetyl-2-O-2-propenyl-.beta.-D-galactopyranosyl)-, triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 244076-93-5 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl 4-O-(2-O-2-propenyl-.beta.-D-galactopyranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 244076-96-8 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl 2,3,6-tris-O-(phenylmethyl)-4-O-[3-O-(phenylmethyl)-2-O-2-propenyl-.beta.-D-galactopyranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 244076-97-9 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl 4-O-[6-O-benzoyl-3-O-(phenylmethyl)-2-O-2-propenyl-.beta.-D-galactopyranosyl]-2,3,6-tris-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 244076-98-0 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl O-2,3,4,6-tetrakis-O-(phenylmethyl)-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-6-O-benzoyl-3-O-(phenylmethyl)-2-O-2-propenyl-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2,3,6-tris-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244076-99-1 HCAPLUS

CN .beta.-D-Glucopyranoside, methyl O-2,3,4,6-tetrakis-O-(phenylmethyl)-
.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-3-O-(phenylmethyl)-2-O-2-
propenyl-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2,3,6-tris-O-
(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 244077-00-7 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl O-2,3,4,6-tetrakis-O-(phenylmethyl)-
.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-3,6-bis-O-(phenylmethyl)-2-O-2-
propenyl-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2,3,6-tris-O-
(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 244077-01-8 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl O-2,3,4,6-tetrakis-O-(phenylmethyl)-
.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-2-O-(2-hydroxyethyl)-3,6-bis-O-
(phenylmethyl)-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2,3,6-tris-O-
(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 244077-02-9 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl O-2,3,4,6-tetrakis-O-(phenylmethyl)-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-2-O-[2-[[(4-nitrophenoxy)carbonyl]oxy]ethyl]-3,6-bis-O-(phenylmethyl)-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2,3,6-tris-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 2-A



RN 244077-03-0 HCAPLUS
CN .beta.-D-Glucopyranoside, 2',2''''-O-[(2-hydroxy-1,3-propanediyl)bis(iminocarbonyloxy-2,1-ethanediyl)]bis[methyl O-2,3,4,6-tetrakis-O-(phenylmethyl)-.beta.-D-galactopyranosyl-(1.fwdarw.4)-O-3,6-bis-O-(phenylmethyl)-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2,3,6-tris-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 1-B



PAGE 2-A





PAGE 2-B

RN 244077-04-1 HCAPLUS
CN .beta.-D-Glucopyranoside, 2',2''''-O-[[2-[[(4-nitrophenoxy)carbonyl]oxy]-1,3-propanediyl]bis(iminocarbonyloxy-2,1-ethanediyl)]bis[methyl O-2,3,4,6-tetrakis-O-(phenylmethyl)-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-3,6-bis-O-(phenylmethyl)-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2,3,6-tris-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



RN 244077-05-2 HCAPLUS
CN .beta.-D-Glucopyranoside, 2',2''''-O-[[2-[[[(8-aminooctyl)amino]carbonyl]oxy]-1,3-propanediyl]bis(iminocarbonyloxy-2,1-ethanediyl)]bis[methyl O-2,3,4,6-tetrakis-O-(phenylmethyl)-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-3,6-bis-O-(phenylmethyl)-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2,3,6-tris-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 2-A







PAGE 2-B





PAGE 3-A

PAGE 3-B



RN 244077-06-3 HCAPLUS
CN .beta.-D-Glucopyranoside, 2',2''''-O-[[2-[[[(8-aminooctyl)amino]carbonyl]oxy]-1,3-propanediyl]bis(iminocarbonyloxy-2,1-ethanediyl)]bis[methyl O-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-.beta.-D-galactopyranosyl-(1.fwdarw.4)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 1-B



PAGE 2-A

PAGE 2-B

RN 244077-07-4 HCAPLUS
CN .beta.-D-Glucopyranoside, 2',2''''-O-[[2-[[[[8-[(2-ethoxy-3,4-dioxo-1-cyclobuten-1-yl)amino]octyl]amino]carbonyl]oxy]-1,3-propanediyl]bis(iminocarbonyloxy-2,1-ethanediyl)]bis[methyl O-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-.beta.-D-galactopyranosyl-(1.fwdarw.4)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 2-A



PAGE 2-B



RN 244077-08-5 HCAPLUS
CN Acetic acid, [[3-[[2,3,4,6-tetrakis-O-[3-[(2-methoxy-2-oxoethyl)thio]propyl]-.beta.-D-glucopyranosyl]oxy]propyl]thio]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244077-09-6 HCAPLUS
CN Acetamide, N-(2-aminoethyl)-2-[[3-[[2,3,4,6-tetrakis-O-[3-[[2-[(2-aminoethyl)amino]-2-oxoethyl]thio]propyl]-.beta.-D-glucopyranosyl]oxy]propyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 258857-10-2 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl 4-O-[4,6-O-(phenylmethylene)-2-O-2-propenyl-.beta.-D-galactopyranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 258857-11-3 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl 2,3,6-tris-O-(phenylmethyl)-4-O-[3-O-(phenylmethyl)-4,6-O-(phenylmethylene)-2-O-2-propenyl-.beta.-D-galactopyranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **98-88-4**, Benzoyl chloride **100-39-0 106-95-6**, Allyl bromide, reactions **107-15-3**, 1,2-Ethanediamine, reactions **373-44-4**, 1,8-Diaminooctane **616-29-5**, 1,3-Diamino-2-hydroxypropane **1125-88-8**, .alpha.,.alpha.-Dimethoxytoluene **2365-48-2**, Methyl thioglycolate **5231-87-8 7693-46-1**, 4-Nitrophenyl chloroformate **41110-63-8 63976-06-7 102674-58-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction; compds., including saccharide compds., for treatment of bacterial infections, and prepn. thereof)

RN 98-88-4 HCAPLUS
CN Benzoyl chloride (8CI, 9CI) (CA INDEX NAME)



RN 100-39-0 HCAPLUS
CN Benzene, (bromomethyl)- (9CI) (CA INDEX NAME)



RN 106-95-6 HCAPLUS
CN 1-Propene, 3-bromo- (9CI) (CA INDEX NAME)



RN 107-15-3 HCAPLUS
CN 1,2-Ethanediamine (9CI) (CA INDEX NAME)



RN 373-44-4 HCAPLUS
CN 1,8-Octanediamine (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 616-29-5 HCAPLUS
CN 2-Propanol, 1,3-diamino- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 1125-88-8 HCAPLUS
CN Benzene, (dimethoxymethyl)- (9CI) (CA INDEX NAME)



RN 2365-48-2 HCAPLUS
CN Acetic acid, mercapto-, methyl ester (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 5231-87-8 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3,4-diethoxy- (9CI) (CA INDEX NAME)



RN 7693-46-1 HCAPLUS
CN Carbonochloridic acid, 4-nitrophenyl ester (9CI) (CA INDEX NAME)



RN 41110-63-8 HCAPLUS
CN .alpha.-D-Galactopyranosyl chloride, 2,3,4,6-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 63976-06-7 HCAPLUS
CN .beta.-D-Glucopyranoside, 2-propenyl 2,3,4,6-tetra-O-2-propenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 102674-58-8 HCAPLUS
CN D-Glucose, 4-O-[6-O-(1-methoxy-1-methylethyl)-3,4-O-(1-methylethylidene)-.beta.-D-galactopyranosyl]-2,3:5,6-bis-O-(1-methylethylidene)-, dimethyl acetal (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L41 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2003 ACS
AN 1999:635458 HCAPLUS
DN 131:228948
TI Preparation of dendrimer oligosaccharides for treatment of bacterial dysentery
IN Bundle, David R.; Kitov, Pavel; Read, Randy J.; Ling, Hong; Armstrong, Glen

PA The Governors of the University of Alberta, Can.
SO U.S., 27 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K031-70
ICS A61K031-74; A61K031-745; A61K031-785
NCL 514025000
CC 33-4 (Carbohydrates)
Section cross-reference(s): 1, 10, 63
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 5962423	A	19991005	US 1998-130495	19980807	
	US 6310043	B1	20011030	US 1999-317290	19990524	<--
	CA 2339198	AA	20000217	CA 1999-2339198	19990806	
	WO 2000008467	A2	20000217	WO 1999-CA725	19990806	
	WO 2000008467	A3	20000706			
	W: AU, CA, JP					
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
	AU 9951450	A1	20000228	AU 1999-51450	19990806	
	AU 754331	B2	20021114			
	EP 1102779	A2	20010530	EP 1999-936219	19990806	
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
PRAI	US 1998-130495	A2	19980807			
	US 1999-317290	A	19990524			
	WO 1999-CA725	W	19990806			

AB Compds. which bind to shiga-like toxins (SLT) assocd. with enteric E. coli infection, compns. including the compds., methods for the neutralization of (SLT) in a patient, and methods for the diagnosis of enteric E. coli infection are disclosed. The compds. MFC-(LA)n-(BM)n were prepd. as shiga-like toxins wherein; MFC is a multifunctional core mol., LA is a linker arm, BM is a bridging mol. which includes two or more di- or trisaccharides, and which can optionally include large oligosaccharides, n is, independently, between 3 and 20, the di- or trisaccharide moiety are optionally linked to between one and eight addnl. saccharide moieties, and include an individual saccharide moiety selected from the group consisting of .alpha.Gal(1-4).beta.Gal, .alpha.Gal(1-4).beta.Gal(1-4).beta.GlcNAc, and .alpha.Gal(1-4).beta.Gal(1-4).beta.Glc, the bridging moieties are bound to at least one linker arm, the linker arms are, independently, C6-20 straight, branched or cyclic alkanes, in which one or more of the carbons may optionally be replaced with an O, S, or amine, and the linker arms can optionally be functionalized at one or more positions with a functional group selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic. The di- or tri-saccharide moieties themselves are active in binding to the SLTs. The presence of a plurality of bridged dimers of the di- and tri-saccharides is responsible for the increased binding affinity of the compds. relative to the di- and tri-saccharides themselves. The compds., when administered in a timely fashion to a patient suffering from enteric E. coli infection, inhibit progression of this infection into hemolytic uremic syndrome (HUS).

ST hemolytic uremic syndrome inhibitor dendrimer oligosaccharide prepn; shiga like toxin bactericide E coli oligosaccharide prepn; dendrimer oligosaccharide prepn cytotoxicity antibacterial

IT Toxins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Shiga-like toxin; prepn. of dendrimer oligosaccharides for treatment of bacterial dysentery)

IT Kidney, disease
(hemolytic-uremic syndrome; prepn. of dendrimer oligosaccharides for treatment of bacterial dysentery)
IT Antibacterial agents
Cytotoxicity
Dysentery
Escherichia coli
(prepn. of dendrimer oligosaccharides for treatment of bacterial dysentery)
IT Dendritic polymers
Oligosaccharides, preparation
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of dendrimer oligosaccharides for treatment of bacterial dysentery)
IT **244077-03-0P 244077-07-4P 244094-61-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of dendrimer oligosaccharides for treatment of bacterial dysentery)
IT **373-44-4**, 1,8-Diaminooctane **492-61-5**, .beta.-D-Glucopyranose **616-29-5**, 1,3-Diamino-2-hydroxypropane **5231-87-8 7693-46-1**, 4-Nitrophenyl chloroformate **41110-63-8 244076-90-2 244077-04-1**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of dendrimer oligosaccharides for treatment of bacterial dysentery)
IT **63976-06-7P 244076-91-3P 244076-92-4P 244076-93-5P 244076-94-6P 244076-95-7P 244076-96-8P 244076-97-9P 244076-98-0P 244076-99-1P 244077-00-7P 244077-01-8P 244077-02-9P 244077-05-2P 244077-06-3P 244077-08-5P 244077-09-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of dendrimer oligosaccharides for treatment of bacterial dysentery)
RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Abbas, S; Sialic Acids Proc Japan-Germany Symp 1988, P22
(2) Altman, D; Practical Statistics for Medical Research 1st ed 1991, P179
(3) Amvam-Zollo; Carbohy Res 1986, V150, P199 HCAPLUS
(4) Anon; WO 93/08209 1993 HCAPLUS
(5) Armstrong; US 5620858 1997 HCAPLUS
(6) Armstrong; US 5679653 1997 HCAPLUS
(7) Armstrong; Infect Immun 1987, V55, P1294 HCAPLUS
(8) Armstrong; J Infect Dis 1991, V164, P1160 HCAPLUS
(9) Boyd; Nephron 1989, V51, P207 MEDLINE
(10) Calderwood; Proc Natl Acad Sci (USA) 1987, V84, P4364
(11) Chernyak, Y; Carbo Res 1984, V128, P269
(12) Cimolai; The Journal of Pediatrics 1990, V117, P676
(13) Cohen; J Biol Chem 1987, V262, P17088 HCAPLUS
(14) Cox; Carbohy Res 1978, V62, P245 HCAPLUS
(15) Dahmen, J; Carboh Res 1983, V118, P292 HCAPLUS
(16) Dahmen, J; Carboh Res 1984, V127, P15 HCAPLUS
(17) DeGrandis; J Biol Chem 1989, V264, P12520 HCAPLUS
(18) Ekborg, G; Carboh Res 1982, V110, P55 HCAPLUS
(19) Fernandez-Santana, V; J Carboh Chem 1989, V8(3), P531 HCAPLUS
(20) Frechet; US 5041516 1991 HCAPLUS
(21) Fugedi, P; Glycoconjugate J 1987, V4, P97 HCAPLUS
(22) Gannon; J Gen Microbiol 1990, V136, P1125 HCAPLUS

(23) Gozzini; US 5807971 1998 HCAPLUS
(24) Lemieux; US 4137401 1979 HCAPLUS
(25) Lemieux; US 4238473 1980 HCAPLUS
(26) Lemieux; US 4362720 1982 HCAPLUS
(27) Margerum; US 5834020 1998 HCAPLUS
(28) Ratcliffe; US 5079353 1992 HCAPLUS
(29) Tomalia; US 5527524 1996 HCAPLUS
(30) Tomalia; US 5714166 1998 HCAPLUS

IT **244077-03-0P 244077-07-4P 244094-61-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of dendrimer oligosaccharides for treatment of bacterial dysentery)

RN 244077-03-0 HCAPLUS

CN .beta.-D-Glucopyranoside, 2',2''''-O-[(2-hydroxy-1,3-propanediyl)bis(iminocarbonyloxy-2,1-ethanediyl)]bis[methyl O-2,3,4,6-tetrakis-O-(phenylmethyl)-.beta.-D-galactopyranosyl-(1.fwdarw.4)-O-3,6-bis-O-(phenylmethyl)-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2,3,6-tris-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 1-B



PAGE 2-A





PAGE 2-B



RN 244077-07-4 HCAPLUS
CN .beta.-D-Glucopyranoside, 2',2''''-O-[[2-[[[[8-[(2-ethoxy-3,4-dioxo-1-cyclobuten-1-yl)amino]octyl]amino]carbonyl]oxy]-1,3-propanediyl]bis(iminocarbonyloxy-2,1-ethanediyl)]bis[methyl O-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-.beta.-D-galactopyranosyl-(1.fwdarw.4)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 2-A



PAGE 2-B



RN 244094-61-9 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl O-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-2-O-(2-hydroxyethyl)-.beta.-D-galactopyranosyl-(1.fwdarw.4)-, decaester with [2-[[[[8-[[3,4-dioxo-2-[[2-[[[[2-[[2,3,4,6-tetrakis-O-[2-[[2-[[2-[[2-[[8-[[[2-(carboxyamino)-1-[(carboxyamino)methyl]ethoxy]carbonyl]amino]octyl]amino]-3,4-dioxo-1-cyclobuten-1-yl]amino]ethyl]amino]-2-oxoethyl]thio]ethyl]-.beta.-D-glucopyranosyl]oxy]ethyl]thio]acetyl]amino]ethyl]amino]-1-cyclobuten-1-yl]amino]octyl]amino]carbonyl]oxy]-1,3-propanediyl]bis[carbamic acid] (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT **373-44-4**, 1,8-Diaminooctane **492-61-5**,
.beta.-D-Glucopyranose **616-29-5**, 1,3-Diamino-2-hydroxypropane
5231-87-8 7693-46-1, 4-Nitrophenyl chloroformate
41110-63-8 244076-90-2 244077-04-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of dendrimer oligosaccharides for treatment of bacterial dysentery)
RN 373-44-4 HCAPLUS
CN 1,8-Octanediamine (6CI, 8CI, 9CI) (CA INDEX NAME)

$H_2N-(CH_2)_8-NH_2$

RN 492-61-5 HCAPLUS
CN .beta.-D-Glucopyranose (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 616-29-5 HCAPLUS
CN 2-Propanol, 1,3-diamino- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 5231-87-8 HCAPLUS
CN 3-Cyclobutene-1,2-dione, 3,4-diethoxy- (9CI) (CA INDEX NAME)



RN 7693-46-1 HCAPLUS
CN Carbonochloridic acid, 4-nitrophenyl ester (9CI) (CA INDEX NAME)



RN 41110-63-8 HCAPLUS
CN .alpha.-D-Galactopyranosyl chloride, 2,3,4,6-tetrakis-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244076-90-2 HCAPLUS
CN D-Glucose, 4-O-[6-O-(1-methoxy-1-methylethyl)-3,4-O-(1-methylethylidene)-.beta.-D-galactopyranosyl]-2,3:5,6-bis-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244077-04-1 HCAPLUS
CN .beta.-D-Glucopyranoside, 2',2''''-O-[[2-[[(4-nitrophenoxy)carbonyl]oxy]-1,3-propanediyl]bis(iminocarbonyloxy-2,1-ethanediyl)]bis[methyl O-2,3,4,6-tetrakis-O-(phenylmethyl)-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-3,6-bis-O-(phenylmethyl)-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2,3,6-tris-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



IT **63976-06-7P 244076-91-3P 244076-92-4P**
244076-93-5P 244076-94-6P 244076-95-7P
244076-96-8P 244076-97-9P 244076-98-0P
244076-99-1P 244077-00-7P 244077-01-8P
244077-02-9P 244077-05-2P 244077-06-3P
244077-08-5P 244077-09-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of dendrimer oligosaccharides for treatment of bacterial dysentery)

RN 63976-06-7 HCAPLUS

CN .beta.-D-Glucopyranoside, 2-propenyl 2,3,4,6-tetra-O-2-propenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244076-91-3 HCAPLUS
CN D-Glucopyranose, 4-O-(3,4,6-tri-O-acetyl-2-O-2-propenyl-.beta.-D-galactopyranosyl)-, tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244076-92-4 HCAPLUS
CN .alpha.-D-Glucopyranosyl chloride, 4-O-(3,4,6-tri-O-acetyl-2-O-2-propenyl-.beta.-D-galactopyranosyl)-, triacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 244076-93-5 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl 4-O-(2-O-2-propenyl-.beta.-D-galactopyranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 244076-94-6 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl 4-O-[4,6-O-[(S)-phenylmethylene]-2-O-2-propenyl-.beta.-D-galactopyranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 244076-95-7 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl 2,3,6-tris-O-(phenylmethyl)-4-O-[3-O-(phenylmethyl)-4,6-O-[(S)-phenylmethylene]-2-O-2-propenyl-.beta.-D-galactopyranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 244076-96-8 HCAPLUS

CN .beta.-D-Glucopyranoside, methyl 2,3,6-tris-O-(phenylmethyl)-4-O-[3-O-(phenylmethyl)-2-O-2-propenyl-.beta.-D-galactopyranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 244076-97-9 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl 4-O-[6-O-benzoyl-3-O-(phenylmethyl)-2-O-2-propenyl-.beta.-D-galactopyranosyl]-2,3,6-tris-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 244076-98-0 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl O-2,3,4,6-tetrakis-O-(phenylmethyl)-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-6-O-benzoyl-3-O-(phenylmethyl)-2-O-2-propenyl-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2,3,6-tris-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244076-99-1 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl O-2,3,4,6-tetrakis-O-(phenylmethyl)-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-3-O-(phenylmethyl)-2-O-2-propenyl-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2,3,6-tris-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 244077-00-7 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl O-2,3,4,6-tetrakis-O-(phenylmethyl)-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-3,6-bis-O-(phenylmethyl)-2-O-2-propenyl-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2,3,6-tris-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 244077-01-8 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl O-2,3,4,6-tetrakis-O-(phenylmethyl)-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-2-O-(2-hydroxyethyl)-3,6-bis-O-(phenylmethyl)-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2,3,6-tris-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 244077-02-9 HCAPLUS
CN .beta.-D-Glucopyranoside, methyl O-2,3,4,6-tetrakis-O-(phenylmethyl)-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-2-O-[2-[[(4-nitrophenoxy)carbonyl]oxy]ethyl]-3,6-bis-O-(phenylmethyl)-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2,3,6-tris-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 2-A



RN 244077-05-2 HCAPLUS
CN .beta.-D-Glucopyranoside, 2',2''''-O-[[2-[[[(8-aminooctyl)amino]carbonyl]oxy]-1,3-propanediyl]bis(iminocarbonyloxy-2,1-ethanediyl)]bis[methyl O-2,3,4,6-tetrakis-O-(phenylmethyl)-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-3,6-bis-O-(phenylmethyl)-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2,3,6-tris-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 2-A







PAGE 2-B





PAGE 3-A

PAGE 3-B



RN 244077-06-3 HCAPLUS
CN .beta.-D-Glucopyranoside, 2',2''''-O-[[2-[[[(8-aminooctyl)amino]carbonyl]oxy]-1,3-propanediyl]bis(iminocarbonyloxy-2,1-ethanediyl)]bis[methyl O-.alpha.-D-galactopyranosyl-(1.fwdarw.4)-O-.beta.-D-galactopyranosyl-(1.fwdarw.4)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

PAGE 1-A



PAGE 1-B



PAGE 2-A

PAGE 2-B

RN 244077-08-5 HCAPLUS
CN Acetic acid, [[3-[[2,3,4,6-tetrakis-O-[3-[(2-methoxy-2-oxoethyl)thio]propyl]-.beta.-D-glucopyranosyl]oxy]propyl]thio]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 244077-09-6 HCAPLUS
CN Acetamide, N-(2-aminoethyl)-2-[[3-[[2,3,4,6-tetrakis-O-[3-[[2-[(2-aminoethyl)amino]-2-oxoethyl]thio]propyl]-.beta.-D-glucopyranosyl]oxy]propyl]thio]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





L41 ANSWER 5 OF 6 HCAPLUS COPYRIGHT 2003 ACS
AN 1999:238153 HCAPLUS
DN 131:19206
TI Synthesis of neoglycoconjugate dendrimers
AU Tsvetkov, Dmitry E.; Cheshev, Pavel E.; **Tuzikov, Alexander B.**; Pazynina, Galina V.; **Bovin, Nikolai V.**; Rieben, Robert; Nifant'ev, Nikolay E.
CS N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, 117913, Russia
SO Mendeleev Communications (1999), (2), 47-50
CODEN: MENCEX; ISSN: 0959-9436
PB Russian Academy of Sciences
DT Journal
LA English
CC 33-4 (Carbohydrates)
Section cross-reference(s): 15
AB A series of polydentate dendritic neoglycoconjugates which contain 4, 8, 16, 32 B-disaccharide ligands were designed as probes to assess the influence of inter-ligand distance on binding to anti-B-disaccharide Igs.
ST structure activity binding Ig neoglycoconjugate dendrimer synthesis; neoglycoconjugate dendrimer synthesis disaccharide binding Ig
IT Polyamines
Polyamines
Polyamines
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(polyamide-, dendrimers; synthesis of neoglycoconjugate dendrimers and the influence of inter-ligand distance on binding to anti-B-disaccharide Igs)
IT Dendritic polymers
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(polyamide-polyamines; synthesis of neoglycoconjugate dendrimers and the influence of inter-ligand distance on binding to anti-B-disaccharide Igs)
IT Polyamides, preparation
Polyamides, preparation
Polyamides, preparation
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(polyamine-, dendrimers; synthesis of neoglycoconjugate dendrimers and the influence of inter-ligand distance on binding to anti-B-disaccharide Igs)
IT Structure-activity relationship
(synthesis of neoglycoconjugate dendrimers and the influence of

inter-ligand distance on binding to anti-B-disaccharide Igs)
IT Disaccharides
Glycoconjugates
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis of neoglycoconjugate dendrimers and the influence of inter-ligand distance on binding to anti-B-disaccharide Igs)
IT Immunoglobulins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(synthesis of neoglycoconjugate dendrimers and the influence of inter-ligand distance on binding to anti-B-disaccharide Igs)
IT **26937-01-9DP**, PAMAM, .alpha.-D-Gal(1.fwdarw.3)-.beta.-D-Gal terminated **26937-01-9P**, PAMAM
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(dendritic; synthesis of neoglycoconjugate dendrimers and the influence of inter-ligand distance on binding to anti-B-disaccharide Igs)
IT **96-33-3**, Methyl acrylate **107-15-3**, 1,2-Ethanediamine, reactions **124-09-4**, 1,6-Hexanediamine, reactions **32564-25-3 201667-63-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis of neoglycoconjugate dendrimers and the influence of inter-ligand distance on binding to anti-B-disaccharide Igs)
IT **194867-28-2P 226408-71-5P 226408-74-8P 226408-77-1P 226408-79-3P 226408-80-6P 226408-84-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of neoglycoconjugate dendrimers and the influence of inter-ligand distance on binding to anti-B-disaccharide Igs)
IT **226408-73-7P 226408-81-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of neoglycoconjugate dendrimers and the influence of inter-ligand distance on binding to anti-B-disaccharide Igs)
RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Aoi, K; Macromolecules 1995, V28, P5391 HCAPLUS
(2) Ashton, P; Chem Eur J 1996, V2, P1115 HCAPLUS
(3) Duncan, R; Proc Int Symp Control Rel Bioact Mater 1996, V23, P105
(4) Gitsov, I; J Am Chem Soc 1996, V118, P3785 HCAPLUS
(5) Gitsov, I; Macromolecules 1993, V26, P6536 HCAPLUS
(6) Korchagina, E; Bioorg Khim 1992, V18, P283 HCAPLUS
(7) Korchagina, E; Russ J Bioorg Chem 1992, V18, P153
(8) Koren, E; 2nd International Congress on Xenontransplantation, Transplant Proc 1994, V26, P1166 MEDLINE
(9) Lindhorst, T; Angew Chem Int Ed Engl 1996, V35, P1953 HCAPLUS
(10) Lindhorst, T; Glycoconj J 1998, V15, P605 HCAPLUS
(11) Mammen, M; Angew Chem Int Ed Engl 1998, V37, P2754
(12) Marquart, M; J Mol Biol 1980, V141, P369 HCAPLUS
(13) Newkome, G; Angew Chem Int Ed Engl 1998, V37, P307 HCAPLUS
(14) Newkome, G; Dendritic Molecules 1996
(15) Page, D; Bioconj Chem 1997, V8, P114
(16) Paul, L; Xenontransplantation 1991, P47
(17) Rieben, R; Xenontransplantation 1995, V2, P98
(18) Tomalia, D; Angew Chem Int Ed Engl 1990, V29, P138
(19) Tomalia, D; Macromolecules 1986, V19, P2466 HCAPLUS
(20) Zanini, D; Carbohydrate Mimics: Concepts and Methods 1998
(21) Zanini, D; J Am Chem Soc 1997, V119, P2088 HCAPLUS
(22) Zanini, D; J Org Chem 1996, V61, P7348 HCAPLUS
IT **26937-01-9DP**, PAMAM, .alpha.-D-Gal(1.fwdarw.3)-.beta.-D-Gal

terminated **26937-01-9P**, PAMAM
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(dendritic; synthesis of neoglycoconjugate dendrimers and the influence of inter-ligand distance on binding to anti-B-disaccharide Igs)
RN 26937-01-9 HCAPLUS
CN 2-Propenoic acid, methyl ester, polymer with 1,2-ethanediamine (9CI) (CA INDEX NAME)

CM 1

CRN 107-15-3
CMF C2 H8 N2



CM 2

CRN 96-33-3
CMF C4 H6 O2



RN 26937-01-9 HCAPLUS
CN 2-Propenoic acid, methyl ester, polymer with 1,2-ethanediamine (9CI) (CA INDEX NAME)

CM 1

CRN 107-15-3
CMF C2 H8 N2



CM 2

CRN 96-33-3
CMF C4 H6 O2



IT **96-33-3**, Methyl acrylate **107-15-3**, 1,2-Ethanediamine, reactions **124-09-4**, 1,6-Hexanediamine, reactions **32564-25-3 201667-63-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis of neoglycoconjugate dendrimers and the influence of inter-ligand distance on binding to anti-B-disaccharide Igs)
RN 96-33-3 HCAPLUS

CN 2-Propenoic acid, methyl ester (9CI) (CA INDEX NAME)



RN 107-15-3 HCAPLUS
CN 1,2-Ethanediamine (9CI) (CA INDEX NAME)



RN 124-09-4 HCAPLUS
CN 1,6-Hexanediamine (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 32564-25-3 HCAPLUS
CN Hexanedioic acid, bis(4-nitrophenyl) ester (9CI) (CA INDEX NAME)



RN 201667-63-2 HCAPLUS
CN .beta.-D-Galactopyranoside, 3-aminopropyl 3-O-.alpha.-D-galactopyranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **194867-28-2P 226408-71-5P 226408-74-8P 226408-77-1P 226408-79-3P 226408-80-6P 226408-84-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of neoglycoconjugate dendrimers and the influence of inter-ligand distance on binding to anti-B-disaccharide Igs)

RN 194867-28-2 HCAPLUS
CN .beta.-Alanine, N,N'-1,6-hexanediylbis[N-(3-methoxy-3-oxopropyl)-, dimethyl ester (9CI) (CA INDEX NAME)



RN 226408-71-5 HCAPLUS
CN Propanamide, 3,3',3'',3'''-(1,6-hexanediyldinitrilo)tetrakis[N-(2-aminoethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—NH_2

RN 226408-74-8 HCAPLUS
CN 4,7,11,18,22,25-Hexaazaoctacosanedioic acid, 11,18-bis[3-[[2-[bis(3-methoxy-3-oxopropyl)amino]ethyl]amino]-3-oxopropyl]-4,25-bis(3-methoxy-3-oxopropyl)-8,21-dioxo-, dimethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 226408-77-1 HCAPLUS
CN 4,7,11,18,22,25-Hexaazaoctacosanediamide, N,N'-bis(2-aminoethyl)-4,25-bis[3-[(2-aminoethyl)amino]-3-oxopropyl]-11,18-bis[3-[[2-[bis[3-[(2-aminoethyl)amino]-3-oxopropyl]amino]ethyl]amino]-3-oxopropyl]-8,21-dioxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-B

RN 226408-79-3 HCAPLUS
CN 4,7,11,14,18,25,29,32,36,39-Decaazadotetracontanedioic acid, 11,32-bis[3-[[2-[bis(3-methoxy-3-oxopropyl)amino]ethyl]amino]-3-oxopropyl]-18,25-bis[7-[3-[[2-[bis(3-methoxy-3-oxopropyl)amino]ethyl]amino]-3-oxopropyl]-14-(3-methoxy-3-oxopropyl)-3,10,17-trioxo-18-oxa-4,7,11-triazanonadec-1-yl]-4,39-bis(3-methoxy-3-oxopropyl)-8,15,28,35-tetraoxo-, dimethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B



PAGE 2-A







PAGE 3-A





PAGE 3-B



PAGE 4-A



PAGE 4-B



RN 226408-80-6 HCAPLUS
CN 4,7,11,14,18,25,29,32,36,39-Decaazadotetracontanediamide, 18,25-bis[20-amino-14-[3-[(2-aminoethyl)amino]-3-oxopropyl]-7-[3-[[2-[bis[3-[(2-aminoethyl)amino]-3-oxopropyl]amino]ethyl]amino]-3-oxopropyl]-3,10,17-trioxo-4,7,11,14,18-pentaazaeicos-1-yl]-N,N'-bis(2-aminoethyl)-4,39-bis[3-[(2-aminoethyl)amino]-3-oxopropyl]-10,32-bis[3-[[2-[bis[3-[(2-aminoethyl)amino]-3-oxopropyl]amino]ethyl]amino]-3-oxopropyl]-8,15,28,35-tetraoxo- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 1-B



PAGE 1-C









PAGE 2-A







PAGE 2-B





PAGE 2-C



RN 226408-84-0 HCAPLUS
CN Hexanoic acid, 6-[[3-[(3-O-.alpha.-D-galactopyranosyl-.beta.-D-galactopyranosyl)oxy]propyl]amino]-6-oxo-, 4-nitrophenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **226408-73-7P 226408-81-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of neoglycoconjugate dendrimers and the influence of inter-ligand distance on binding to anti-B-disaccharide Igs)
RN 226408-73-7 HCAPLUS
CN 7,10,14,21,25,28-Hexaazatetratriacontanediamide, N,N'-bis[3-[(3-O-.alpha.-D-galactopyranosyl-.beta.-D-galactopyranosyl)oxy]propyl]-14,21-bis[3-[[2-[[6-[[3-[(3-O-.alpha.-D-galactopyranosyl-.beta.-D-galactopyranosyl)oxy]propyl]amino]-1,6-dioxohexyl]amino]ethyl]amino]-3-oxopropyl]-6,11,24,29-tetraoxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



PAGE 2-B



RN 226408-81-7 HCAPLUS
CN Hexanediamide, N,N''-1,6-hexanediylbis[N'-[3-[(3-O-.alpha.-D-galactopyranosyl-.beta.-D-galactopyranosyl)oxy]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L41 ANSWER 6 OF 6 HCAPLUS COPYRIGHT 2003 ACS
AN 1998:219739 HCAPLUS
DN 128:278972
TI Glycoconjugates as virus cell adhesion inhibitors
IN **Bovin, Nikolai**; Matrosovich, Mikhail; **Tuzikov, Alexandr**

; **Chinarev, Alexandr; Gambaryan, Alexandra**; Robertson, James

PA Syntesome Gesellschaft fuer Med. Biochemie m.b.H., Germany; Bovin, Nikolai; Matrosovich, Mikhail; Tuzikov, Alexandr; Chinarev, Alexandr; Gambaryan, Alexandra; Robertson, James

SO PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DT Patent
LA German
IC ICM A61K047-48
CC 1-5 (Pharmacology)
Section cross-reference(s): 33

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9814215	A2	19980409	WO 1997-EP5389	19971001
	WO 9814215	A3	19980820		
	W: CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	DE 19640791	A1	19980416	DE 1996-19640791	19961002
	EP 863769	A1	19980916	EP 1997-948758	19971001
	EP 863769	B1	20020703		
	R: AT, BE, CH, DE, FR, GB, IT, LI				
	JP 2002514186	T2	20020514	JP 1998-516240	19971001
	AT 219947	E	20020715	AT 1997-948758	19971001
PRAI	DE 1996-19640791	A	19961002		
	WO 1997-EP5389	W	19971001		

OS MARPAT 128:278972

GI



I

AB The host-cell adhesion by human influenza viruses is inhibited by 6'-sialyl-N-acetyllactosamine conjugates [I; R1, R3 = acyl, thioacyl; R2 = H, OH, ZA; A = (substituted) alkyl, (substituted) aryl; Z = O, S, NH; R4 = H, acyl; X = O, S, C1-4 alkylene; W = bifunctional spacer; P = multivalent carrier [polyacrylate, (N-substituted) polyacrylamide, (N-substituted) methacrylamide, poly(acrylic acid), polycarbonate, polyester, polyamide, polyanhydride, polyiminocarbonate, poly(ortho ester), polydioxanone, polyphosphazene, poly(hydroxy carboxylic acid), poly(amino acid), polysaccharide, protein, dextran, chitosan, glucan, liposomes, microparticles]]. I can bind to human influenza A (H1 and H3) and B viruses which have not been adapted by culturing in chicken eggs and therefore have an unaltered structure of the receptor-binding site on the

viral hemagglutinin; they are useful prophylactically and therapeutically against influenza virus infections. Thus, 6'-sialyl-N-acetyllactosamine ammonium salt was converted to its N-glycyl deriv. (II) by reaction with chloroacetic anhydride. Poly(4-nitrophenyl acrylate) was 20% substituted with II by reaction with II and ethanolamine to form II-substituted poly[N-(2-hydroxyethyl)acrylamide]. The affinity const. of this polymer conjugate for all strains of influenza A and B virus tested was in the range 0.01-0.1 .mu.M, as detd. by its inhibition of viral binding to fetuin.

ST virus cell adhesion inhibitor sialylacetyllactosamine deriv

IT Cell adhesion
(by viruses; glycoconjugates as virus cell adhesion inhibitors)

IT Liposomes
Microparticles
(conjugates with sialylacetyllactosamine; glycoconjugates as virus cell adhesion inhibitors)

IT Polyamides, biological studies
Polyanhydrides
Polycarbonates, biological studies
Polyesters, biological studies
Polyphosphazenes
Polysaccharides, biological studies
Proteins, general, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates with sialylacetyllactosamine; glycoconjugates as virus cell adhesion inhibitors)

IT Animal virus
Antiviral agents
Influenza virus
(glycoconjugates as virus cell adhesion inhibitors)

IT Glycoconjugates
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(glycoconjugates as virus cell adhesion inhibitors)

IT Carboxylic acids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxy, polymers, conjugates with sialylacetyllactosamine; glycoconjugates as virus cell adhesion inhibitors)

IT Hemagglutinins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(of influenza virus, binding of; glycoconjugates as virus cell adhesion inhibitors)

IT Esters, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ortho acid, polymers, conjugates with sialylacetyllactosamine; glycoconjugates as virus cell adhesion inhibitors)

IT Polyamides, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(poly(amino acids), conjugates with sialylacetyllactosamine; glycoconjugates as virus cell adhesion inhibitors)

IT Receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(virus binding to, inhibition of; glycoconjugates as virus cell adhesion inhibitors)

IT **78969-47-8**, 6'-Sialyl-N-acetyllactosamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(carrier conjugates; glycoconjugates as virus cell adhesion inhibitors)

IT **31621-87-1**, Polydioxanone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates with sialylacetyllactosamine; glycoconjugates as virus cell adhesion inhibitors)

IT **75455-20-8DP**, conjugates with sialylacetyllactosamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(glycoconjugates as virus cell adhesion inhibitors)

IT **79-10-7D**, 2-Propenoic acid, esters, polymers, conjugates with sialylacetyllactosamine, biological studies **79-41-4D**, esters, polymers, conjugates with sialylacetyllactosamine **463-77-4D**, Carbamic acid, esters, polymers, conjugates with sialylacetyllactosamine, biological studies **6703-56-6D**, Carbonimidic acid, esters, polymers, conjugates with sialylacetyllactosamine **9003-01-4D**, conjugates with sialylacetyllactosamine **9003-05-8D**, Polyacrylamide, conjugates with sialylacetyllactosamine **9004-54-0D**, Dextran, conjugates with sialylacetyllactosamine, biological studies **9012-72-0D**, Glucan, conjugates with sialylacetyllactosamine **9012-76-4D**, Chitosan, conjugates with sialylacetyllactosamine **25014-12-4D**, Polymethacrylamide, conjugates with sialylacetyllactosamine **31621-87-1D**, Polydioxanone, conjugates with sialylacetyllactosamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(glycoconjugates as virus cell adhesion inhibitors)

IT **541-88-8**, Chloroacetic anhydride **3655-05-8** **4742-00-1**, Tetrakis(aminomethyl)methane **29248-48-4** **32564-25-3**, Bis(4-nitrophenyl) adipate **67391-52-0**, Poly(4-nitrophenyl acrylate) **205753-11-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(glycoconjugates as virus cell adhesion inhibitors)

IT **205753-09-9P** **205753-10-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(glycoconjugates as virus cell adhesion inhibitors)

IT **151704-01-7P** **205753-07-7P** **205830-65-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(glycoconjugates as virus cell adhesion inhibitors)

IT **78969-47-8**, 6'-Sialyl-N-acetyllactosamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(carrier conjugates; glycoconjugates as virus cell adhesion inhibitors)

RN 78969-47-8 HCAPLUS

CN D-Glucose, O-(N-acetyl-.alpha.-neuraminosyl)-(2.fwdarw.6)-O-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2-(acetylamino)-2-deoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **31621-87-1**, Polydioxanone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(conjugates with sialylacetyllactosamine; glycoconjugates as virus cell adhesion inhibitors)
RN 31621-87-1 HCAPLUS
CN Poly[oxy(1-oxo-1,2-ethanediyl)oxy-1,2-ethanediyl] (9CI) (CA INDEX NAME)



IT **75455-20-8DP**, conjugates with sialylacetyllactosamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(glycoconjugates as virus cell adhesion inhibitors)
RN 75455-20-8 HCAPLUS
CN 2-Propenamide, N,N-bis(2-hydroxyethyl)-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 10196-26-6
CMF C7 H13 N O3



IT **79-10-7D**, 2-Propenoic acid, esters, polymers, conjugates with sialylacetyllactosamine, biological studies **79-41-4D**, esters, polymers, conjugates with sialylacetyllactosamine **463-77-4D**,

Carbamic acid, esters, polymers, conjugates with sialylacetyllactosamine, biological studies **6703-56-6D**, Carbonimidic acid, esters, polymers, conjugates with sialylacetyllactosamine **9003-01-4D**, conjugates with sialylacetyllactosamine **9003-05-8D**, Polyacrylamide, conjugates with sialylacetyllactosamine **9004-54-0D**, Dextran, conjugates with sialylacetyllactosamine, biological studies **9012-72-0D**, Glucan, conjugates with sialylacetyllactosamine **9012-76-4D**, Chitosan, conjugates with sialylacetyllactosamine **25014-12-4D**, Polymethacrylamide, conjugates with sialylacetyllactosamine **31621-87-1D**, Polydioxanone, conjugates with sialylacetyllactosamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(glycoconjugates as virus cell adhesion inhibitors)

RN 79-10-7 HCAPLUS
CN 2-Propenoic acid (9CI) (CA INDEX NAME)



RN 79-41-4 HCAPLUS
CN 2-Propenoic acid, 2-methyl- (9CI) (CA INDEX NAME)



RN 463-77-4 HCAPLUS
CN Carbamic acid (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 6703-56-6 HCAPLUS
CN Carbonimidic acid (9CI) (CA INDEX NAME)



RN 9003-01-4 HCAPLUS
CN 2-Propenoic acid, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 79-10-7
CMF C3 H4 O2



RN 9003-05-8 HCAPLUS
CN 2-Propenamide, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 79-06-1
CMF C3 H5 N O



RN 9004-54-0 HCAPLUS
CN Dextran (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9012-72-0 HCAPLUS
CN D-Glucan (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 9012-76-4 HCAPLUS
CN Chitosan (8CI, 9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
RN 25014-12-4 HCAPLUS
CN 2-Propenamide, 2-methyl-, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 79-39-0
CMF C4 H7 N O



RN 31621-87-1 HCAPLUS
CN Poly[oxy(1-oxo-1,2-ethanediyl)oxy-1,2-ethanediyl] (9CI) (CA INDEX NAME)



IT **541-88-8**, Chloroacetic anhydride **3655-05-8**
4742-00-1, Tetrakis(aminomethyl)methane **29248-48-4**
32564-25-3, Bis(4-nitrophenyl) adipate **67391-52-0**,
Poly(4-nitrophenyl acrylate) **205753-11-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(glycoconjugates as virus cell adhesion inhibitors)
RN 541-88-8 HCAPLUS

CN Acetic acid, chloro-, anhydride (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 3655-05-8 HCAPLUS
CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-, 4-nitrophenyl ester (9CI) (CA INDEX NAME)



RN 4742-00-1 HCAPLUS
CN 1,3-Propanediamine, 2,2-bis(aminomethyl)- (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 29248-48-4 HCAPLUS
CN 2,5-Pyrrolidinedione, 1-[[N-[(1,1-dimethylethoxy)carbonyl]glycylglycyl]oxy]- (9CI) (CA INDEX NAME)



RN 32564-25-3 HCAPLUS
CN Hexanedioic acid, bis(4-nitrophenyl) ester (9CI) (CA INDEX NAME)



RN 67391-52-0 HCAPLUS
CN 2-Propenoic acid, 4-nitrophenyl ester, homopolymer (9CI) (CA INDEX NAME)

CM 1

CRN 2123-85-5
CMF C9 H7 N O4



RN 205753-11-3 HCAPLUS
CN D-Glucose, O-(N-acetyl-.alpha.-neuraminosyl)-(2.fwdarw.6)-O-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2-(acetylamino)-2-deoxy-, ammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **205753-09-9P 205753-10-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(glycoconjugates as virus cell adhesion inhibitors)
RN 205753-09-9 HCAPLUS
CN 2,5,9,12-Tetraazatridecanedioic acid, 7,7-bis[[[[[(1,1-dimethylethoxy)carbonyl]amino]acetyl]amino]methyl]-4,10-dioxo-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 205753-10-2 HCAPLUS
CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]glycylglycyl-, tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT **151704-01-7P 205753-07-7P 205830-65-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(glycoconjugates as virus cell adhesion inhibitors)
RN 151704-01-7 HCAPLUS
CN Acetamide, N-[O-(N-acetyl-.alpha.-neuraminosyl)-(2.fwdarw.6)-O-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2-(acetylamino)-2-deoxy-.beta.-D-glucopyranosyl]-2-amino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 205753-07-7 HCAPLUS
CN Hexanoic acid, 6-[[2-[[O-(N-acetyl-.alpha.-neuraminosyl)-(2.fwdarw.6)-O-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2-(acetylamino)-2-deoxy-.beta.-D-glucopyranosyl]amino]-2-oxoethyl]amino]-6-oxo-, 1-(4-nitrophenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 205830-65-5 HCAPLUS
CN Glycine, N-[6-[[2-[[O-(N-acetyl-.alpha.-neuraminosyl)-(2.fwdarw.6)-O-.beta.-D-galactopyranosyl-(1.fwdarw.4)-2-(acetylamino)-2-deoxy-.beta.-D-glucopyranosyl]amino]-2-oxoethyl]amino]-1,6-dioxohexyl]glycylglycyl-, 3,3',3'',3'''-tetraamide with 2,2-bis(aminomethyl)-1,3-propanediamine (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***